DESIGN AND DEVELOPMENT OF A MICROFLUIDIC DEVICE FOR THE ASSESSMENT OF FIRST-PASS METABOLISM by Corrado, Brunella
5 
 
UNIVERSITÀ DEGLI STUDI DI NAPOLI FEDERICO II 
 
 
 
DEPARTMENT OF CHEMICAL, MATERIALS AND PRODUCTION 
ENGINEERING (DICMAPI) 
 
PhD in “INDUSTRIAL PRODUCTS AND PROCESSES ENGINEERING” 
XXIX cycle 
 
 
 
 
 
“DESIGN AND DEVELOPMENT OF A MICROFLUIDIC DEVICE FOR THE 
ASSESSMENT OF FIRST-PASS METABOLISM” 
 
 
 
 
 
 
 
 
 
Supervisor   
Prof. Paolo Antonio Netti 
Advisor  
Dr. Francesco Urciuolo 
Dr. Giorgia Imparato  
Dr. Vincenza De Gregorio  
Coordinator PhD Student 
Prof. Giuseppe Mensitieri Brunella Corrado 
 
 
 
 
 
 
2014/2017 
 
 
 
Contents 
Introduction ..................................................................................................................................... 5 
Chapter 1 .......................................................................................................................................... 7 
1 State of the art .......................................................................................................................... 7 
 First-pass metabolism ......................................................................................................... 7 1.1
 Hepatic first-pass metabolism and biliary excretions .................................................. 8 1.1.1
 Intestinal first-pass metabolism ................................................................................. 11 1.1.2
 Prediction of first-pass metabolism .................................................................................. 13 1.2
 In vivo model ............................................................................................................. 13 1.2.1
 In vitro liver model .................................................................................................... 15 1.2.2
 In vitro gut model ...................................................................................................... 20 1.2.3
 Microfluidics  technologies ............................................................................................... 23 1.3
 General principles of microfluidics ........................................................................... 23 1.3.1
 Materials .................................................................................................................... 24 1.3.2
 Fabrication ................................................................................................................. 24 1.3.3
 Liver-on-chip .................................................................................................................... 26 1.4
 Gut-on chip ....................................................................................................................... 30 1.5
 First-pass metabolism in vitro model ................................................................................ 31 1.6
 Microfluidic model of first-pass metabolism .................................................................... 31 1.7
Chapter 2 ........................................................................................................................................ 33 
2 A novel three dimensional hepatic model on chip: functionality study and  xenobiotic 
toxicity assessment ......................................................................................................................... 33 
 Introduction ....................................................................................................................... 33 2.1
 Materials and Methods ...................................................................................................... 35 2.2
 Cell type ..................................................................................................................... 35 2.2.1
 Microscaffold production .......................................................................................... 35 2.2.2
 HepG2-Microtissues production ................................................................................ 35 2.2.3
 HepG2-Spheroid formation ....................................................................................... 36 2.2.4
 Cell viability .............................................................................................................. 36 2.2.5
 Histological and immunohistochemical analysis ...................................................... 37 2.2.6
 Diameter evaluation of micromodules ...................................................................... 37 2.2.7
 Immunofluorescence analysis .................................................................................... 37 2.2.8
 Albumin and Urea measurement ............................................................................... 37 2.2.9
 
 
 
 
 Microdevice fabrication ............................................................................................. 38 2.2.10
 Perfusion culture and ethanol injury .......................................................................... 39 2.2.11
 On line cell viability: Cell auto-fluorescence ............................................................ 39 2.2.12
 Analysis of oxidative stress ....................................................................................... 40 2.2.13
 Statistical analysis ...................................................................................................... 41 2.2.14
 Results ............................................................................................................................... 41 2.3
 Time evolution of viability and morphology of µTPs and spheroid model .............. 41 2.3.1
 Functional assessment of HepG2-µTPs and HepG2-spheroids ................................. 44 2.3.2
 Liver-on-chip bioreactor ............................................................................................ 48 2.3.3
 Ethanol cytotoxicity assessment under perfusion culture .......................................... 49 2.3.4
 Assessment of hepatic functions ................................................................................ 50 2.3.5
 Analysis of oxidative stress ....................................................................................... 51 2.3.6
 Discussion ......................................................................................................................... 52 2.4
 Conclusion ........................................................................................................................ 55 2.5
Chapter 3 ........................................................................................................................................ 56 
3 A microfluidic platform to recreate air-liquid interface of 3D human intestinal 
equivalent ....................................................................................................................................... 56 
 Introduction ....................................................................................................................... 56 3.1
 Materials and Methods ...................................................................................................... 57 3.2
 Microdevice fabrication ............................................................................................. 57 3.2.1
 Perfusion culture optimization ................................................................................... 58 3.2.2
 Mathematical model CFD simulation ........................................................................ 58 3.2.3
 Cell type ..................................................................................................................... 59 3.2.4
 Intestinal microtissues precursors: fabrication and characterization ......................... 59 3.2.5
 Organotypic intestinal culture development .............................................................. 60 3.2.6
Three dimensional intestinal stromal equivalents ................................................................... 60 
Three-dimensional human intestine equivalent production ..................................................... 61 
 3D-ISE on a chip and 3D-HIE on a chip ................................................................... 61 3.2.7
 ECM microarchitecture of 3D-ISE ............................................................................ 61 3.2.8
Collagen fraction ..................................................................................................................... 61 
Degree of collagen assembly (CA) evaluation ........................................................................ 62 
Correlation length .................................................................................................................... 62 
Determination of collagen content .......................................................................................... 63 
 Immunofluorescence and histological analysis ......................................................... 64 3.2.9
 Alkaline Phosphatase assay (ALP Activity) .............................................................. 65 3.2.10
 Statistical analysis ...................................................................................................... 65 3.2.11
 Results ............................................................................................................................... 65 3.3
 Microdevice fabrication ............................................................................................. 65 3.3.1
 
 
 
 
 Perfusion culture optimization ................................................................................... 66 3.3.2
 Mathematical model CFD simulation ........................................................................ 67 3.3.3
 Collagen organization ................................................................................................ 68 3.3.4
 Organotypic intestinal culture development .............................................................. 71 3.3.5
 Histological analysis .................................................................................................. 72 3.3.6
 Immunofluorescence analysis .................................................................................... 73 3.3.7
 Alkaline Phosphatase assay (ALP Activity) .............................................................. 74 3.3.8
 Discussion ......................................................................................................................... 75 3.4
 Conclusion ........................................................................................................................ 78 3.5
Chapter 4 ........................................................................................................................................ 79 
4 Human first-pass metabolism on a chip ............................................................................... 79 
 Introduction ....................................................................................................................... 79 4.1
 Materials and Methods ...................................................................................................... 80 4.2
 Cell type ..................................................................................................................... 80 4.2.1
 Intestinal microtissue precursors: fabrication and characterization .......................... 81 4.2.2
 Three-dimensional human intestine equivalent production ....................................... 81 4.2.3
 HepG2-Microtissues production ................................................................................ 82 4.2.4
 Microfluidic device fabrication ................................................................................. 82 4.2.5
 First-pass on a chip culture conditions ...................................................................... 83 4.2.6
 Measurement of selective permeation properties ...................................................... 84 4.2.7
 Immunofluorescence assay ........................................................................................ 84 4.2.8
 Alcohol dehydrogenase release assay ........................................................................ 84 4.2.9
 Statistical analysis ...................................................................................................... 85 4.2.10
 Results ............................................................................................................................... 85 4.3
 Microfluidic device fabrication ................................................................................. 85 4.3.1
 Measurement of selective permeation properties ...................................................... 86 4.3.2
 Immunofluorescence assay ........................................................................................ 87 4.3.3
 Alcohol dehydrogenase release assay ........................................................................ 88 4.3.4
 Discussion ......................................................................................................................... 89 4.4
 Conclusion ........................................................................................................................ 90 4.5
Chapter 5 ........................................................................................................................................ 91 
5 Future perspectives ................................................................................................................ 91 
Bibliography ................................................................................................................................... 93 
 
5 
 
Introduction  
Orally administration of drugs is one of the preferred methods because it is easy and the 
compliance of the patient is high. Once ingested, a drug is dissolved and metabolized into the 
gastrointestinal fluid (GI), then crosses the intestinal and liver barrier where it is subjected to the 
first-pass metabolism. First-pass metabolism consists into the sequential actions of intestinal and 
hepatic metabolism to which a drug is subjected that leads to a reduction of its concentration 
before it reaches the blood circulation. First-pass extraction is associated with poor bioavailability 
of a variety of drugs. One of the limitation to oral drug bioavailability is the pre-systemic 
extraction by both the liver and the gut wall. In order to avoid low bioavailability and poor 
therapeutic effects of the drugs, it is necessary to predict the elimination route of the new 
developed drugs. Conventional in vivo and in vitro test are not so predictive and correlated to a 
numerous disadvantages, such as high costs, elevated time for the screening, not ethical and 
difficulties for high-throughput screening. With the rapid progresses in the microfabrication 
technologies, new in vitro microfluidic platforms are developed. For this purpose, organs-on-a-
chip show great promises in the field of predictive/personalized medicine and are gaining 
increasing attention especially for the development of new drugs. According to that, the scope of 
this thesis is to propose a microfluidic model to simulate and mimic the physiological mechanism 
of the first-pass metabolism of orally ingested drugs. In the first part of the thesis, there is an 
introduction about the in vivo mechanism involved in the in process of first-pass metabolism. In 
particular are explained the principal organs involved in the first-pass metabolism, that is the 
intestine, where a first metabolic process takes place, and the liver where the quote of drugs is 
metabolized again. New bioengineered in vitro models to assess first-pass metabolism are 
presented with a particular attention on 3D intestine and liver models. Furthermore, the first 
chapter is focused on the recent studies on organ-on-chip device that can recapitulate the in vivo 
physiology and microenvironment, with the relative steps of fabrications. In the chapter 2, we first 
focused on the production of an innovative hepatic three dimensional tissue and made a 
comparison with the spheroid model, as gold standard model. Then we designed and validated a 
microfluidic device for the culturing of 3D HepG2 microtissues, in order to have a dynamic 
perfusion culture. The chapter 3 is focused on the fabrication of an organotypic intestinal 3D 
tissues cultured in both static and dynamic conditions. This 3D intestinal tissues are obtained by 
bottom-up approach of intestinal stromal microtissues, moulded in a maturation chamber. A Caco-
2 epithelium was seeded on the surface of the biohybrid tissue. Furthermore, a gut-on-chip 
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microfluidic device was fabricated in order to obtain an air-liquid interface culture. The 
microfluidic gut-on-chip device was also used to study the stroma assembly and modification in 
the two different culture conditions. The combination of the two hepatic and intestine model on 
chip, is addressed in chapter 4. In this forth chapter, indeed a microfluidic biochip can 
accommodate both hepatic microtissues and 3D human intestinal equivalent. By the selective 
communication of the two tissues recreated into the biochip, it is possible to reproduce in vitro the 
mechanisms of orally ingested drugs and xenobiotics compounds.  
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Chapter 1 
1 State of the art 
 First-pass metabolism 1.1
The selection of drug administration route is based on the specific site of action, the clinical 
situation of the patients, and the rate of the drug absorption. It is widely accepted that prescription 
of orally formulated drugs is the preferred method of administration, because it is easy, and 
patient’s compliance and comfort are high [1]. Once ingested, the drug is dissolved and 
metabolized into the gastrointestinal fluids (GI), then cross the intestinal and liver barrier where it 
is subjected to the first-pass metabolism. First-pass metabolism consists into the sequential actions 
of intestinal and hepatic metabolism to which a drug is subjected that lead to a reduction of its 
concentration before it reaches the blood circulation (Figure 1.1). Sometimes only a small amount 
of active drug emerges from the liver to the rest of the circulatory system. The fraction of oral 
dose, which reaches the target site as intact drug is refereed to oral bioavailability (𝐹𝑜𝑟𝑎𝑙).  
 
Figure 1.1: Schematic representation of first-pass metabolism. Once ingested a drug undergoes to a series of modifications that 
reduce its dose until it reaches the bloodstream [2]. 
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The oral drug bioavailability is determined by the product of the fraction of dose absorbed from 
the GI tract (𝐹𝑎), and the fraction of absorbed dose that escapes the metabolism at the intestine 
(𝐹𝐺) and liver 𝐹𝐻. This is expressed mathematically in the Eq.(1) [3]:  
 
𝐹𝑜𝑟𝑎𝑙 = 𝐹𝑎 + 𝐹𝐺 + 𝐹𝐻                                                                                                          (1) 
 
It is clear that first-pass metabolism reduces the bioavailability of the drugs. Poor oral 
bioavailability (𝐹𝑜𝑟𝑎𝑙) as been established as one of a reason for the failure of drug candidates in 
pre-clinical and clinical development. A lead compound should therefore have adequate 𝐹𝑜𝑟𝑎𝑙 to 
achieve the necessary drug plasma concentration time profile efficiently. 𝐹𝑜𝑟𝑎𝑙 also has to be 
predictable in order to prevent undesirable toxic side effects or sub-therapeutic drug plasma 
concentration [4]. 
As mentioned before, one of the limitation to oral drug bioavailability is the pre-systemic 
extraction by both the liver and the gut wall. First-pass extraction is associated with poor 
bioavailability of a variety of drugs [2]. Metabolism is the principal mechanism for the elimination 
of most of the drugs on the market and is a major component of pre-systemic extraction [5]. 
Metabolism can be divided into two phases, phase I and II. Phase I metabolism consists in the 
process of functionalization in which functional groups like hydroxyl, carboxylic, amino are 
introduced to the drug’s structure via oxidation, reduction and hydrolysis. Phase II reactions 
involve conjugation between high polar moiety to either phase I metabolite or the parent drug to 
facilitate biliary or urinary excretion. Among the metabolic enzymes, cytochrome P450s (CYP) 
(phase I) and the UDP-glucuronosyltransferases (UGT) (phase II) are responsible for the majority 
of metabolic elimination. More than three quarters of the metabolic reactions of the 200 most 
prescribed are mediated by the CYP enzymes, whilst CYP3A4 is accountable for almost 46% of 
these reactions [6].  
 Hepatic first-pass metabolism and biliary excretions  1.1.1
The liver is one of the largest organ in our body whose functional unit is the haptic lobule. This 
organ has a wide range of functions like glycogen storage, plasma protein synthesis, production of 
bile and body detoxification from xenobiotic compounds (Figure 1.2-A). The liver is a highly 
vascularized organ with a stratified cellular structure [7]. Hepatocytes [parenchymal cells (PCs)] 
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are separated from non-parenchymal cells (NPCs) by a protein-enriched interface called the Space 
of Disse (SoD) (Figure 1.2-B). 
 
Figure 1.2: A) Schematic structure of the liver lobule. B) Hepatic sinusoids, where blood circulates, are characterized by sinusoidal 
endothelial and Kupffer cells. Hepatocytes, or liver parenchymal cells are localized to the space of Disse, distant from the sinusoid. 
Natural killer (NK) and invariant NK T (NKT) cells are abundant in the liver. Lym: lymphocytes, including NK cells, NKT cells, 
and other lymphocytes [8]. 
 
Hepatocytes account for approximately 70% of the volume of the liver, other cells are comprised 
of NPCs such as liver sinusoidal endothelial cells (LSECs), hepatic stellate cells (HSCs), and 
Kupffer cells (KCs). The SoD contains extracellular matrix (ECM) proteins, proteoglycans, and 
other molecules that enable hepatic cells to maintain their differentiated state. Hepatocytes 
abundantly express a large repertoire of enzymes for phase I and II metabolism. The contribution 
of the liver to pre-systemic extraction and therefore to 𝐹𝐻 can occur by means of two mechanisms: 
first-pass metabolism and biliary excretion. The factors affecting the liver first-pass metabolism 
are the same factors governing the hepatic clearance: blood flow, unbound fraction of drug in the 
blood/plasma, enzyme abundance, the affinity and the capacity of the metabolic enzymes to bio-
transform these drugs, expressed as hepatic intrinsic clearance (CLint) [9]. About liver enzymes, 
the major ones involved in the hepatic first-pass metabolism include CYPs, UDP-
glucuronosyltransferases (UGTs) and sulfotransferases (SULTs). Cytochrome P450 enzymes are 
the most important enzyme systems of phase I metabolism, a microsomal superfamily of 
A B 
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isoenzymes that catalyzes the oxidation of many drugs. CYPs are membrane proteins found in 
either the endoplasmic reticulum (ER) or mitochondrial membrane [2]. The electrons are supplied 
by NADPH–CYP450 reductase, a flavoprotein that transfers electrons from NADPH (the reduced 
form of nicotinamide adenine dinucleotide phosphate) to CYP450. There are 57 isoform of CYP 
enzymes that are categorized to 18 different families and 43 subfamilies. CYP450 enzymes are 
commonly expressed in the liver, but also found in the intestine, skin kidney and brain. CYP3A is 
the most important and abundant isoform of these enzymes. CYPs can be induced or inhibited by 
many drugs and substances resulting in drug interactions in which one drug enhances the toxicity 
or reduces the therapeutic effect of another drug. As the liver contains the greatest abundance of 
drug-metabolizing CYPs, CYP substrates are susceptible to efficient first-pass metabolism, which 
leads to low bioavailability. UDP-glucuronosyltransferases (UGTs) are the second main enzymes 
involved in the first-pass drug metabolism. The reaction catalysed by the UGT enzymes involves 
the addition of a glucuronic acid moiety to xenobiotics and is the most important pathway for the 
human body's elimination of the most frequently prescribed drugs. It is also the major pathway for 
foreign chemicals (dietary, environmental, pharmaceutical), removal for most drugs, dietary 
substances, toxins and endogenous substances. UGT is present in humans, other animals, plants, 
and bacteria. Sulfonate conjugation is an important pathway in the biotransformation of numerous 
xeno- and endo-biotics such as drugs, chemical carcinogens, hormones, bile acids, 
neurotransmitters, peptides, and lipids. The universal sulfonate donor for these reactions is 3′-
phosphoadenosine 5′-phosphosulfate (PAPS), and the transfer of sulfonate  to a hydroxyl or 
amino-group is catalysed by a super gene family of enzymes called sulfotransferases (SULTs). In 
the case of most xenobiotics and small endogenous substrates, sulfonation has generally been 
considered a detoxification pathway leading to more water-soluble products and thereby aiding 
their excretion via the kidneys or bile. For a drug like acetaminophen or a neurotransmitter such as 
dopamine, this is certainly the case. The abundance of the metabolic enzymes in the liver is higher 
than in any other organ in the human body [2]. In Caucasians the total abundance of CYP 
enzymes in the liver has been reported to be 0.43 nmol/mg of microsomal protein, where the most 
abundant phase I enzymes is CYP3A, followed by CYP2C, CYP1A2, CYP2E1, CYP2A6 and 
CYP2D6 [10]-[11]. Biliary excretion, on the other hand, is affected by the drug efflux to the 
canalicular space between hepatocytes and it is believed to occur mainly through active transport 
[12]-[13]. Transporters located in the canalicular membrane include P-gp, MRP2 and BCRP, 
therefore the substrate affinity for these transporters is an important factor for biliary excretion 
[14]. There are a number of drug-specific physicochemical factors that can influence biliary 
excretion, such as molecular weight, polarity and lipophilicity. The impact of biliary excretion in 
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drug bioavailability has been demonstrated for several drugs such as cardiovascular, anticancer, 
anti-infective and biologically active peptides. However, determination of the extent of biliary 
excretion in humans is very difficult, and therefore is mostly estimated by employing animal 
models, in vitro cell cultures or in silico models [12],[14].  
 Intestinal first-pass metabolism  1.1.2
Besides liver, it is important to know how intestine attend the first-pass metabolism. In order to 
understand the permeation of a drug through the gastrointestinal (GI) tract membrane it is 
important to have a general understanding of the anatomical and physiological factors affecting 
drug absorption in the human GI tract. The GI is an organ system which digests food, absorb 
energy and nutrients, and excretes the waste products as feci and urine. It can be divided into 
different segments: mouth cavity, esophagus, stomach, small intestine, and large intestine. The 
absorption of the drug can occur in all the segments of the GI but in particular in the stomach, 
small intestine and colon [15]-[16]. The small intestine is the major portion of the GI tract 
accounting for around 81% of the total intestinal length and is the major site for digestion and 
absorption of nutrients and xenobiotics. It consists of three major parts: duodenum, jejunum and 
ileum whose lengths are approximately 8%, 37% and 55% of the total length of the small 
intestine, respectively. The mucosa is the membrane that covers the luminal portion of the 
intestine and consists of a single layer of epithelial cells over a vascularized lamina propria. To 
maximize the efficiency of absorption and digestion, the human small intestine possesses highly 
complex 3D microenvironment. In particular, it forms circular folds on whose surface possesses 
finger like protrusions called intestinal villi. Each villus is about 0.5-1.0 mm high, and there are 
20-40 villi per mm
2
 [18]. 
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Figure 1.3: Structure of the small intestinal membrane. In the villi, the absorptive cells (enterocytes) rest over the vessel rich 
mucosa where the absorbed nutrients, drugs and xenobiotics are transported to the portal circulation. The enterocytes display a 
brush border structure in the apical side formed by microvilli. 
 
The intestinal contribution to first-pass metabolism has been subject to increasing interest during 
the last decades and it is believed to play a major role for determining oral bioavailability [18-20]. 
As in the liver, CYP3A enzymes are the most abundant enzymes in the human intestinal wall, 
accounting for almost 80% of the small intestine CYP content [10]. CYP enzymes are strategically 
located at the villous part of enterocytes and their presence varies along the small intestine. 
Quantification studies showed that CYP3A4 abundance decreases from the proximal duodenum 
towards the distal ileum, being highly expressed in the jejunal segment [21]. This distribution 
pattern can have an impact on the bioavailability of CYP3A4 substrates administered as controlled 
release formulations [22]. Even though the CYP3A4 abundance is about 1% of that in the human 
liver [23], it plays an important role in the intestinal pre-systemic extraction for several drugs [24]. 
In addition, it has been hypothesized that both CYP3A4 and P-gp might act together as barriers for 
the absorption of drugs and xenobiotics. This hypothesis is supported by their location within the 
enterocytes, overlapping affinity for several substrates and suggestions of coordinated regulation 
between them [24-25]. The factors influencing first-pass gut wall metabolism and therefore 
affecting the 𝐹𝐺  are similar to those governing the hepatic clearance: intestinal blood flow, 
intestinal fraction unbound and intestinal intrinsic clearance [27]. However, there is a complex 
interplay between drug absorption and intestinal first-pass metabolism, where the factors affecting 
drug absorption might have an impact on the rate and extent of intestinal first-pass extraction (i.e., 
the solubility, permeability, residence time, and inter individual variability) [28].  
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 Prediction of first-pass metabolism 1.2
 
In order to predict the oral bioavailability of new developed drugs, several models for the 
prediction of first-pass metabolism have been developed. These includes both in vitro and in vivo 
approaches during drug discovery process. About drug discovery process, the first step is to 
identify and select a “target”, such as a gene or protein, which can potentially be affected by a 
drug or a molecule. Once the target is established, a promising molecule, or a “lead” is identified 
that can interact with the target. The lead is optimized by screening many similar compounds. The 
first pre-clinically screening is developed with in vitro 2D culture model as well as animal models. 
In vitro methods are widely used to investigate kinetic, metabolic, and toxicity (ADME-Tox) of 
new lead compounds early in the drug discovery process. However, in vitro cell-based assay do 
not provide a realistic model of the environment to which the cells are exposed in the body, for 
example the extracellular matrix environment which provide mechanical support and dynamic 
signalling cues, the exchange of metabolites from one cell type to another and the physiological 
shear stresses from the fluid flow are all missed. This assay also do not takes into account of the 
complexity of multiple organs and their interaction. 
Anyway, if the drug is evaluated positively with cell-based assays, more advanced tests with 
animal models are conducted. Unfortunately, animal models do not always predict the actions of 
drugs accurately, because human metabolism and animal metabolism can differ considerably. 
Because of these differences, it is possible that drug candidates are eliminated even though they 
might be effective in humans. As a result, using an extensive number of animals to study the 
actions of drugs gives rise to ethical concerns, especially because animal model are not so 
predictive.  Indeed, only about 10% of compounds that promised potential in animal models, were 
allowed to enter clinical trials. Anyway, many drugs fail during full clinical development in 
Phases II and III [29], the most expensive phases of drug development, because they have poor 
bioavailability or are considered not clinically safe because of toxic side effects. Since this models 
are not so predictive, there is the need to develop better in vitro models of human and animal 
metabolisms in order to reduce drug development times and costs.  
 In vivo model 1.2.1
During pre-clinical drug discovery, research teams use animal models to test the pharmacokinetic 
characteristics of new drug candidates. The most commonly animal species used in such clinical 
studies are mouse, rats, dogs and non-human primates (NHP) [30]. For intravenous 
administration, human pharmacokinetic parameters such as clearance, half-life and volume of 
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distribution have been predicted empirically from pre-clinical species data by means of allometric 
scaling techniques [31]. Allometric scaling requires the investigation of the desired 
pharmacokinetic parameters in one or more pre-clinical species, where the parameters of interest 
are regressed against a species body size descriptor (usually body weight) and the resulting 
regression equation can be used to predict the value of the parameters in humans [32]. However, 
one of the major drawbacks of allometric scaling is its empirical nature, which does not 
necessarily allows the understanding of the underlying mechanisms that can explain the species 
differences in the pharmacokinetic parameters, such as metabolic clearance [22]. Moreover, the 
usefulness of allometric scaling for the prediction of human pharmacokinetic parameters has been 
questioned due to large prediction errors that can arise from the allometric relationship and the use 
of arbitrary constants with little or no physiological meaning [33]. As a part of the drug 
development process oral bioavailability is usually investigated in pre-clinical species and the 
resulting data is subsequently employed as a part of the lead selection/optimization process. In 
some research teams, thresholds have been set up for oral bioavailability, for instance 20-30% in 
rats, as an indicator of acceptable human oral bioavailability for the new drug candidate [34]. 
Preclinical species seem to provide a good indication of the human oral absorption for certain drug 
candidates. Several groups have demonstrated acceptable correlations levels between the Fa and 
intestinal permeability between humans and pre-clinical species, particularly for rat and monkeys, 
though this correlation was found to be poor in dogs [35,36]. When it comes to oral 
bioavailability, however, a similar relationship remains unclear. One of the first attempts to 
summarize the relationship between human and animal bioavailability was done by Sietsema in 
1989 where he collected bioavailability data for several drugs in humans, rodents, dogs and 
primates, showing a poor interspecies correlation [37], while in 2000 Mahmood also highlighted 
that allometric scaling was not an adequate tool for the direct prediction of human bioavailability 
[38]. From the analysis of the previous datasets it can be noticed that the bioavailability data 
obtained from preclinical species seems to underestimate the value in humans [37], [39]. While 
the reason for this underprediction might not be necessarily clear, as mentioned before, the factors 
governing oral bioavailability are numerous and depend both on the drug-related properties and 
physiological, environmental and population characteristics. Therefore one can speculate that 
interspecies differences in physiological aspects, such as body size, blood flows, plasma proteins, 
GI tract morphology and physiology, enzymatic abundance in the GI tract and liver are probably 
the main contributors for the differences observed in bioavailability. Most of the aforementioned 
comparisons and datasets were based on a limited number of compounds (< 50 compounds) [38] 
[39] [40] whereas the largest dataset is from 1989 and does not differentiate between preclinical 
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species such as rats, mouse and/or rabbits nor include enough data points, especially for the 
analysis of the correlations between monkeys and humans [37]. Interestingly, one of the most 
cited articles when it comes to the comparison between animal and human oral bioavailability is 
based on Sietsema’s review on interspecies bioavailability data [41]. Therefore there is the need 
for an updated, wider and specific dataset that can be employed for the comparison between 
human and animal oral bioavailability, in order to definitely elucidate whether animal data can be 
used for the prediction of human oral bioavailability per se. This dataset can be also used for the 
development of quantitative and qualitative models for the extrapolation of bioavailability values 
from pre-clinical species to human, which can be of value in drug development.  
 In vitro liver model 1.2.2
To understand liver physiology, researchers have relied primarily on hepatocytes cultured as 
monolayers. Primary human hepatocytes are considered the gold standard of in vitro liver models 
in drug development. In the late 1960s Berry et al. [42] extracted viable rat hepatocytes using 
collagenase method. In the 1980s, extraction of human hepatocytes became a more common 
culture assay for drug screening  [43]. However, primary hepatocytes have well-known 
disadvantages, such as limited availability of the liver tissue for cell harvesting, high functional 
variability between hepatocytes from different donors, and difficulty maintaining differentiated 
phenotype and functions in cell cultures. Since primary hepatocytes are not so easy to handle, 
perpetual cell lines represents a potential alternative in drug metabolism and hepatotoxicity 
studies[44]. Some example include HepG2, Hep3B, Huh7, and HepaRG. Anyway these cell lines 
may lack many features of the hepatocytes but sure they have a lot of advantages: good 
availability, unlimited growth, are easy to handle and there isn’t the donor variability. The most 
frequently used liver cell line, HepG2, was derived from the liver tissue of a male patient with 
hepatocellular carcinoma [45]. HepG2 are equal to primary hepatocytes in assessing parent 
compound toxicity, but they have low metabolic activity when cultured on plastic or glass 
surfaces[46]. 
Fortunately, improvements in the culture environment have shown to induce both drug 
metabolizing enzymes and transporters in HepG2 cells [47],[48].  
A recent hepatoma cell line, HepaRG, was derived from a liver tumor of a female patient who 
suffered from the hepatitis C virus and hepatocarcinoma [49]. HepaRG is a superior cell line 
compared to the other immortal hepatic cell lines. It expresses the metabolizing enzymes at a level 
comparable to the primary human hepatocytes [50],[51]. This cell line also expresses several 
active drug transporters [52]. Other advantages of HepaRG are the stability of the phenotype, 
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extends to several weeks in duration [53], and its suitability for toxicity studies [51], [52], [54]. 
HepaRG cells are commercially available as a fully differentiated form that is suitable for drug 
metabolism studies, whereas the original HepaRG hepatic progenitor cell line is a proprietary cell 
line that is provided only to a few research laboratories. The versatile HepaRG progenitor cell line 
expresses bipotent differentiation. At low density, the HepaRG resembles liver progenitors, and in 
the confluent state, the culture is composed of hepatocyte-like and cholangiocytes-like cells 
[50],[55]. Furthermore, the differentiated cells show reverse differentiation to the progenitor 
phenotype while seeded at low density. The xenobiotic metabolism of the HepaRG progenitor is 
initially low, but is induced after several weeks of treatment with dimethyl sulfoxide (DMSO) 
[50]. Because cells on monolayer rapidly loss hepatic phenotype, multicellular cultures have 
gained attention for the promotion of heterotypic interactions [46]. 
The heterotypic co-culture between hepatocytes and non-parenchymal cells allows the increase of 
the phenotype and of the functions of the hepatocytes compared to monoculture for several weeks 
[56]. This effects is due to the direct heterotypic cell-cell contacts, and partially to the paracrine 
influences of cytokines secreted by the surrounding cells [57].  
Co-culture with fibroblasts, hepatic stellate cells, Kupffer cells, or liver sinusoidal endothelial 
cells have improved at least some of the hepatic functions [58]. 
From another point of view, co-culture with NP cells is necessary to recreate hepatotoxicity 
mechanism which require collaboration with different cell type of the liver. Thus, to predict liver 
toxicity from in vitro data, hepatocytes have been co-cultured with immune system cells, such as 
Kupffer cells, a promising type of co-culture. This kind of co-culture seems promising since it 
enhances cytotoxicity to the hepatotoxic chemicals [59],[60]. Several experimental approaches to 
perform this co-culture includes direct co-culturing on standard culture plastic [61], co-culturing 
with collagen layer [62], or culturing in membrane inserts, where different cell types are separated 
by a membrane, but soluble mediators can migrate between the compartments [63]. Moreover, co-
culturing has been performed with cell sheet technology where confluent cell monolayers of 
hepatocytes and non-parenchymal cells are stacked on top of each other [64]. Two dimensional 
co-cultures of PCs and one or more NPCs, such as LSECs [65], fibroblasts [66], or other cell 
types, showed stable hepatic markers for several weeks. Despite co-cultures are clearly 
advantageous in term of cost and time, they do not recapitulate the cellular composition or the 3D 
liver architecture in vivo. Indeed, 3D culture model enable the maintenance of NPC phenotypes 
for longer culture periods and recapitulate more the physiological hepatic microenvironment[67]. 
Despite these advances, closely recreating the hepatic microenvironment remains a challenge. 
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Hepatocytes in our body have a polygonal shape but they lose this characteristic when cultured in 
2D culture, appearing flattened. The flattened cell morphology limits cell-cell interactions, and 
leads to reduce polarization, limiting signaling pathway and liver functions. Hence, research 
groups have been working on the retaining the physiological cell-cell and cell-ECM contact by 
various 3D cell-culture techniques. Hepatic spheroids are simple 3D systems which are formed by 
the natural tendency of the cells to aggregate. Spherical multicellular aggregates, spheroids, are 
formed when the cells self-assemble and re-establish the cell-cell contacts in three dimensions. 
Spheroids culture shows many advantages such as prolonged survival [68],[69], in vivo-like 
characteristics like polarity, enhanced secretion of albumin and urea and formation of bile acids 
[70],[71]. These effects may are obtained from the retention of the 3D architecture, the presence of 
ECM and the high number of cell-cell contacts [68],[72],[73].  
Spheroids formation can be induced by a variety of different techniques including hanging drop 
method, liquid overlay cultures and dynamic bioreactors. In the hanging drop method, cells are 
arranged in small droplets in a plastic slide. Due to the surface tension, liquid can maintain 
droplets when the lid is inverted and cells settled at the bottom of the droplet. A simple method for 
spheroid production involves liquid overlay of a cell suspension over a non-adherent surface, such 
as agar-coated plates. Spheroids can also be formed by culturing in spinner flasks or bioreactors, 
which can provide dynamic conditions preventing cell-substrate contact and promoting cells to 
form aggregates by either stirring or rotating bioreactors. This system can produce large numbers 
of relatively consistent spheroids, but they both require specialized equipment and additional 
processing steps when used for drug testing.  One of the major uses of human spheroids has been 
as a preclinical screening tool for drug candidates because they remain viable and maintain liver 
functions. However, a drawback associated with spheroids is the lack of cell–ECM contacts or 
nutrients for cells that are located in the necrotic core. Cellulose hydrogels, which exhibit 
diffusion coefficients comparable to ECM-derived gels proteins, supported the growth and 
differentiation of HepaRG (hepatic progenitor cells) and HepG2 spheroids with minimal 
cytotoxicity [74]. Encapsulation of HepG2 spheroids in alginate hydrogels led to an increased 
induction of CYP1A1 and CYP3A4 [44]. Recognizing the importance of heterotypic interactions, 
recent studies have encapsulated more than one cell type within spheroids, for example 
endothelial cell cords were formed using a co-culture of human umbilical vein endothelial cells 
(HUVECs) and mouse mesenchymal cells encapsulated in type I collagen [75]. These cords 
resulted in patent blood vessels and albumin promoter activity in hepatocytes. Induced pluripotent 
stem cells (iPSCs), HUVECs, and human mesenchymal stem cells (hMSCs) were cultured 
together to form iPSC derived liver buds (IPSC-LBs), which on transplantation resulted in 
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successful anastomosis to the host vasculature and formation of blood vessels [76]. Hepatic cord-
like structures were also observed, suggesting the maturation of hepatocytes. These major 
developments open new avenues to enhance the complexity and physiological relevance of 
engineered tissues through the inclusion of vasculature in spheroids. Spheroids are convenient and 
relatively simple techniques to simulate in vivo liver microarchitecture. In spite of these 
advantages, the lack of interstitial fluid dynamics, which is highly relevant to drug transport 
within the tissue, is one of the major limitations. 
Scaffold-based systems are a comparable 3D in vitro model for testing novel drugs. In this kind of 
culture, cells are grown in a semi-solid matrix that allows to study the influences of external 
physical factor on micro spheroids growth and signalling. Biomaterials scaffold have been 
produced as synthetic ECM to enable the 3D organization of liver cells. Scaffolds are designed to 
be porous and their mechanical properties should be viscoelastic like natural tissue. The cells are 
seeded on prefabricated scaffolds where they grow on the surface of the pores and may form 3D 
cell assemblies. 3D scaffolds mimic ECM of connective tissues and provide architectural support 
for tissue engineering and regeneration with select cell types. In particular, biodegradable 
scaffolds have been widely used since they may be further suitable for tissue engineering purposes 
[77]. In general, scaffolds can be classified in two groups: natural and synthetic scaffold. Based on 
the nature of the scaffolding materials, they are either biodegradable or non-biodegradable and 
biocompatible or non-biocompatible. Biomaterials, either natural or synthetic, that are 
biodegradable and biocompatible are highly demanded in tissue engineering. The most successful 
synthetic polymers include poly(lactic acid) (PLA), poly(glycolic acid) (PGA), and poly(lactic-co-
glycolic acid) (PLGA). The PLA, PGA, and their derivatives have supported 3D hepatocyte 
growth for up to two weeks [78]. More recently, a cross-linked polystyrene scaffold, Alvetex TM, 
has been shown to support hepatocytes morphology and upregulation of CYP enzymes better than 
the conventional 2D polystyrene plastic ware [79]. 
About natural scaffolds, the most used are the hydrogels. They exhibit low mechanical properties 
but they provide a biomimetic environment that supports cell proliferation and differentiation. 
Most of the hydrogels used are made up of naturally occurring materials or proteins found in the 
ECM, one of the many examples is collagen type I. The scaffold based on the natural alginate 
polymer, has shown to increase the aggregation of primary hepatocytes [80], to maintain albumin 
synthesis of primary hepatocytes [81], and to increase CYP and UGT enzyme activity of 
hepatocyte cells. Selection of the ideal biomaterial scaffold for a given cell type is problematic and 
has been accomplished to date mostly by trial and error. Even if the right biomaterial is available, 
achieving a high enough cell density and the homogeneous cell distribution necessary to construct 
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a viable tissue is extremely time consuming. Furthermore, pre-shaping the scaffold may present 
further difficulties. In order to get over these limitations, efforts have been focused on scaffold-
less tissue engineering and bottom-up approaches which aimed to generate larger tissue by 
assembly small building blocks. This approach try to mimic the in vivo structure of tissues and 
organs which are constituted in repeating small functional units. 
 
Figure 1.4: Schematic diagram of microgel assembly process. Microgel units were synthesized by photolithography, transferred 
into a dish containing mineral oil, and subjected to mechanical agitation applied by manually manipulating a pipette-tip in a back-
and-forth manner[82]. 
An example of a bottom-up approach was used by Du et al. [82], to direct the assembly of cell-
laden microgels to generate 3D tissue with tunable microarchitecture and complexity (Figure 1.4). 
McGuigan and Sefton (2006), proposed another interesting use of modular components for 
generating tissue. In their approach, rod-shaped collagen microgels that were seeded with HepG2 
hepatocytes on the inside and endothelial cells on the surface were "packed" together within a 
bioreactor and perfused with medium [83]. 3D bioprinting has been applied to the development of 
several types of tissues and organs by using different cell types. The bioprinting of functional 
perfusable hepatic constructs is still in its first phase. However, 3D bioprinting techniques have 
been explored to reproduce hepatic constructs with limited function. Metabolically active 3D 
hepatic tissue has been printed using the NovoGen MMX Bioprinter (Organovo Holdings, Inc., 
San Diego, CA, USA). An increased liver-specific function of the tissue (for up to 135 h) 
compared with matched 2D cell cultures was demonstrated. Furthermore, compartment-specific 
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organization was shown for hepatocytes, hepatic stellate cells, and ECs by rudimentary 
microanatomy. The extrusion-based bioprinting technique was used to print alginate-encapsulated 
HepG2 cells, growth factors, and scaffolding materials in an organized 3D architecture [84]. These 
microlivers were dynamically microperfused to mimic an in vivo condition to study drug 
metabolism. Furthermore, this system was also utilized to perform as a model for a 
radioprotection study on liver cells. Netti and co-workers (2010), produced a new microtissue 
precursor assembly strategy (μTP) to produce pieces of viable 3D tissue equivalent in order to 
capture the feature of the native tissue. μTPs were produced by means of dynamic cells seeding of 
bovine fibroblasts on porous gelatin using spinner flask bioreactor [85]. In this culture condition 
the porous structure of microcarriers created a suitable environment for the development of 
fibroblasts and other cells type, as the cells within the porous carrier will experience lower shear 
stress than those encountered with non-porous carriers.   
Ultimately, 3D cultures, both spheroids and scaffold based-models, can contribute to the reduction 
in animal testing and allow for economical savings as well as become a powerful model to 
optimize drug candidates for enhanced tissue distribution and efficacy.  
 
 In vitro gut model 1.2.3
 
Currently, modelling of the GI tract has focused on the small intestine because it is responsible for 
a large portion of digestion and secretion (Figure 1.5).  
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Figure 1.5: (a) Illustration of human small intestine epithelium on crypt–villus axis. (b) A schematic of conventional 2D small 
intestine model. Caco-2 and HT-29 MTX are cultured on the track-etched membrane. (c) A scanning electron microscope image of 
human small intestine villi. 
 
Typical in vitro GI model are characterized by the culture of epithelial monolayer under static 
condition. The cell line commonly used are immortalized or cancerous intestine-like cells, [86] 
such as Caco-2, HT-29, T84, TC-7, and SW620. Among these cell types, Caco-2 and HT-29 cells 
are used extensively as substitutes for enterocytes and goblet cells, respectively [87]. Caco-2 cells 
are derived from human colon carcinoma and have been shown to form a polarized enterocyte-like 
monolayer after 21 days in culture on Transwell inserts where they become fully differentiated 
(Figure 1.3). Polarized Caco-2 monolayers are characterized by the presence of villi, brush border 
enzymes, and drug transporters. Caco-2 cells can be cultured on a variety of biomaterials 
including alginate, collagen, polycarbonate, polystyrene, and Biocoat. This cell line is very 
versatile and it is extremely appealing for use in engineered in vitro models. Unfortunately, in 
terms of xenobiotic transport modelling, such culture models have low permeability because 
Caco-2 monolayer is eight-times smaller than that of human small intestine epithelium, which is 
considered as one of the reasons for poor drug paracellular permeability correlation between 
conventional in vitro models and human small intestine. Additionally, the expression of critical 
phase I and phase II biotransformation enzymes is significantly lower in such cells as compared to 
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in vivo [86]. The P-glycoprotein (P-gp) efflux pump is overexpressed in Caco-2 cells compared to 
the level measured in vivo with primary small intestinal enterocytes, which to some extent 
enhances the transport activity of the epithelium significantly during drug absorption. HT-29 cells 
are also derived from human colon carcinoma and can express mature mucin proteins. Caco-2 
monocultures or co-cultures with HT-29 cells are frequently cultured on the apical side of a 
Transwell insert to mimic the intestinal barrier [88]. Transwell systems have been commonly used 
to assess the effect of environmental chemicals and pharmaceuticals. The permeability of a drug 
or chemical is measured by determining the rate of transport across the monolayer. The viability 
of the cultures has been assessed by tight junction degradation through trans-epithelial electrical 
resistance (TEER) measurements, changes in mitochondrial metabolism and cell viability, 
production of ROS, and changes in protein synthesis. 
However, it should be noted that these stationary 2D cell cultures recapitulate neither the tissue 
architecture of the mucus layer nor the interactions between the epithelium and the stroma in 
intestinal mucosa. This is most important because such interactions involved in tissue 
microenvironment play a dominant role in determining the phenotype and functionality of 
enterocytes, and consequently affecting the process of drug absorption. 
By using three-dimensional culture models for intestinal mucosa tissues it is possible to better 
mimic the in vivo tissue microenvironment. Tissue engineering techniques allowed to develop 3D 
cell culture system for studies of drug toxicity evaluation and replacement therapy.  
With the development of microfabrication and other biomaterial fabrication techniques, 
biomimetic topography has been integrated into in vitro intestinal models to represent human 
small intestine 3D features. One example of 3D intestinal model obtained by microfabrication 
techniques is an human small intestine crypt-like topography fabricated using photolithography 
and transferred to poly(dimethylsiloxane) (PDMS) and collagen membrane substrates [89]. 
Compared with 2D flat substrates, Caco-2 cultured on PDMS substrates with crypt-like 
topography exhibited higher mitochondrial activity and lower alkaline phosphatase activity, 
similar to the cell phenotype in human intestinal crypts [89]. Transepithelial electrical resistance 
(TEER) values were found to be slightly lower for Caco-2 monolayers cultured on topographically 
modified collagen membranes relative to flat collagen controls, suggesting that crypt-like 
topography might affect tight junctions of the Caco-2 monolayer.  
Human small intestine villus structures have also been fabricated by combining different 
microfabrication techniques. 3D printing (3DP) was used to construct porous poly(lactic-
coglycolic acid) (PLGA) villous scaffolds [90]. However, take into account the resolution 
limitation of this technique, porous PLGA villous structures had considerably bigger basal areas 
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than human small intestine villi and hence could not reproduce the dimension and density of the 
villi relevantly. Recently, by combining laser techniques, a collagen villous scaffold was 
fabricated with 0.5 mm villous height and 25 villi per mm
2
 density, with striking similarity to the 
human jejunal villi [91] (Figure 1.5 c,d). By using a custom-made cell culture insert kit, the 
collagen villous scaffold was integrated with a six-well cell culture plate to study drug absorption 
[92]. When cultured on collagen villous scaffold, Caco-2 exhibited differentiation gradients along 
the villous axis, on the top of the villous cells were more columnar and polarized than cells near 
the bottom of the villus, according to the in vivo observation that enterocytes become more 
differentiated when migrating from the crypt to the top of the villus [92]. About TEER 
measurements, Caco-2 monolayers cultured on collagen villous scaffolds showed to be 
significantly lower than 2D controls, and similar to in vivo intestinal values. The apparent 
permeability coefficient (Papp) of the slowly absorbed drug atenolol measured on the collagen 
villous scaffold was 13 times higher than that measured using conventional 2D models, and much 
closer to the average permeability value from perfused human small intestines, suggesting that the 
3D villous model could improve the poor permeability correlation of paracellularly transported 
drugs between in vitro models and native human small intestine.  
Recently, Schweinlin et al. engineered small intestinal organoids using a decellularized small 
intestinal submucosa as a scaffold [93]. CYP3A4 and P-glycoprotein levels were measured and 
compared between organoids cultured alone or on the scaffolds [93]. Both CYP3A4 and P-
glycoprotein levels were more than 3-fold higher in organoids cultured on scaffolds in a bioreactor 
than organoids in a static system.  
 
 Microfluidics  technologies 1.3
 General principles of microfluidics 1.3.1
 
Microfluidic is the science of manipulation of small amounts of fluids (10−9 − 10−18𝐿 ) in micro 
hollow channel. It involves the development of miniaturized devices (microchip) and to control, 
manipulate, and analyze flows in submillimeter dimensions. It is a microsystem technology that 
has been used to generate and precisely tune dynamic fluid flown fluid flows and spatio-temporal 
gradients, as well as deliver nutrients and other chemical cues to cells in a controlled manner [94]. 
Thanks to the small size, fluid flow in the microsystem is laminar and there isn’t the mixing of 
different fluids. Typically, microfluidic systems have a geometry with characteristic dimension 
length on the order of tens to hundred microns. Advantages of this microsystems are easiness of 
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fabrication, low reagent consumption, parallel and rapid processing ability and large-scale 
integration. Microfluidic chips have been developed for various purposes, like real-time PCR, 
immunoassays, whole blood sample preparations, two-dimensional chromatographic separations, 
and to culture cells under flow conditions. It is the creation of networks of interconnecting 
channels that makes the field of microfluidics so powerful.  
 
 
 Materials 1.3.2
Firstly, the development of microfluidic devices was focused on micro-machining and electronic 
application but the emergence of BioMEMS fabrication techniques such as replica moulding has 
opened the development of microfluidic cell culture models in an array of materials platforms 
including synthetic and natural materials as well as bioresorbable systems. 
For the selection of substrate materials for microfluidic device, it is important to take into account 
about some particular characteristics such as optical transparency for cell imaging, the desired 
degree of mechanical rigidity or flexibility, surface chemistry and reactivity and biocompatible. 
Synthetic polymers such as PolyDiMethylSiloxane (PDMS) are the most common platforms for 
microfluidic systems and have been applied to cell culture models based on their high oxygen 
permeability, optical transparency, and easiness of fabrication [95]. In particular, the typical 
characteristic of the PDMS are the high gas permeability that allows sufficient oxygen supply to 
the cells in the microchannels, transparency from ultraviolet to the near infrared wavelength. 
However, the tendency of PDMS to absorb, retain and release other chemicals and some organic 
solvents in an unpredictable fashion has been a problem for different applications. Other used 
materials are, poly(methyl methacrylate) (PMMA), polycarbonate (PC), and polystyrene (PS). 
 
 Fabrication 1.3.3
There is a wide range of microfabrication techniques for constructing microfluidic device. The 
basis for the fabrication processes of most microfluidic devices is photolithography, a set of 
techniques originally developed to integrate semiconductor structures on microelectronic chips. 
Photolithography exploits a photosensitive polymer, so-called photoresist, to pattern chip surfaces. 
Two types of photoresist exist, positive and negative photoresist. When positive photoresist is 
exposed to UV light, the exposed region becomes soluble and the unexposed region is 
polymerized. In the case of negative photoresist, it is the other way around: the exposed region 
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becomes polymerized and the unexposed area is soluble in appropriate solution. Commonly, glass 
or silicon wafers are coated with a thin layer of photoresist. Subsequently, a latent image is 
formed in the resist by exposing it to ultraviolet light through a photomask with opaque and 
transparent regions containing the channel layout of the microchip. After patterning, the 
unpolymerized photoresist is removed by rinsing with an appropriate solvent, leaving the desired 
pattern behind on the wafer. Subsequently, the glass or silicon can be selectively dissolved with an 
appropriate etching solution like hydrofluoric acid (wet-etching) or with e.g. reactive ion etching 
(dry etching), to form the structures in the substrate. However, silicon and glass are rather 
expensive, and silicon is opaque, which means it cannot be used for optical measurements in the 
UV or visible range.  
Another approach is to fabricate chips in polymers, using a process known as soft lithography. 
Instead of using the wafer material to fabricate the chip, the wafer is now used as mold with a 
positive relief of the channel structure. This mold can be re-used multiple times. In this procedure 
thermosetting elastomer like PDMS is poured over the mold, and allowed to polymerize. In this 
case, the thickness of the original photosensitive layer determines the depth of the channel. After 
polymerization, the elastomer with structure can be gently peeled off the wafer (Figure 1.6). The 
open channel structure in the elastomer can be closed by placing another piece of elastomer or 
glass on top of it, to obtain a closed microchip. The bonding of these two pieces occurs by 
chemical interaction without the need of glue. In general, microfluidic devices offer many 
advantages over conventional systems. The biochip are very minute so only small amounts of the 
tested substrates are needed, a fundamental consideration during early drug development 
screening that usually require large amount of compounds. Other advantages are less waste and 
lower reagents costs compared to conventional system. Due to the small dimension, it is possible 
to conduct high-throughput screening analysis in a compact device. The analysis and response 
times are also much faster compared to conventional systems, due in part to the short diffusion 
distances. With microfluidic technology, many new devices and applications have been and 
continue to be developed for various applications, in order to improve on conventional systems or 
to open up new applications. 
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Figure 1.6: Creation of microfluidic devices. A photolithographic process is used to first create a pattern of a photoresist on a 
silicon wafer. Then, soft polymers such as polydimethylsiloxane (PDMS) are cast on the wafer to generate a stamp. This stamp can 
then be irreversibly bonded to a basement substrate (i.e., glass, PDMS, or acrylic) to create microfluidic channels for perfusion of 
cultures [96] 
 Liver-on-chip 1.4
 
The liver has proven to be one of the most difficult organs for drug approval, due to the strong 
interactions it has with other organs, as well as its sensitivity to the metabolism of certain drugs. 
This takes to a high percentage that are removed from the market due to hepatotoxicity. By 
improve the method and the technology to test for toxicity, it will be more easy, fast and safe 
develop new drugs and reach the market [97]. In last years, considerable amount of research has 
been done in the toxicity test area using accurate microfluidic system mimicking the liver 
functions. Incorporating flow into the culture system has been shown to increase and maintain a 
higher level of metabolic functions. Physiologic oxygen gradients can be established in these 
microfluidic systems which can assist in elucidating the physiological mechanisms involved in 
hepatotoxicity [98]. According to the literature there are a lot of valid microfluidic liver models 
that can provide a dynamic, tunable environment emulating in vivo conditions. 
The microscale design of the biochips allow for microscopic imaging, oxygen sensing, 
physiologically relevant ratios of chamber sizes and liquid residence times in each compartment, 
physiological hydrodynamic shear stress, physiological liquid to cell ratios, and requires less 
media and cells.  
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One of the first developed liver microfluidic device was introduced by Lee et al. in 2007.  They 
designed microfluidic devices that mimic the hepatic sinusoid. An endothelial cell-like barrier was 
incorporated to separate different cell types resulting in the preservation of hepatocyte viabilities 
and functionalities [99]. In terms of high throughput screening, Toh et al. [100] created a system 
with separate independent cell culture, so that different drugs concentrations can be 
simultaneously increased. The “3D HepaTox Chip,” is designed to support parallel channels 
containing separate cell cultures, in order to test different level of drug concentration to each 
channel, in particular the hepatotoxicity testing was performed using five model drugs: 
acetaminophen (20mM), diclofenac (1000μM), quinidine (1000μM), rifampin (2000μM) and 
ketoconazole (420μM). Albumin production and various metabolic activities were measured to 
assess liver functionality. Results showed that this microfluidic model was equally capable of the 
functional maintenance of the hepatocytes as a multi-well plate model. Results showed that the 
cells were more sensitive to the drug-mediated hepatotoxicity than the multi-well plate cultures. 
The toxicity data also showed a positive correlation with comparable in vivo toxicity data. Nakao 
et al. [101] focused on functionality of liver cells  by developing a microfluidic cell culture device 
that mimics the microscopic structure of the hepatic cords. Liver specific functions of freshly 
isolated primary hepatocytes decline rapidly due to the lost if their membrane polarity so a new 
technique for maintaining the cells was proposed, in which hepatic activity was prolonged by 
suctioning the cells into the cord-like compartment of the device, creating a “collagen sandwich 
culture”. In this way the aligned hepatocytes were able to self-organize themselves and form bile 
canaliculi along the hepatic cord-like structure as shown by MRP2 and CD147  marker protein.   
Lee et al [102] designed a microfluidic device that contained polyethyleneglycol (PEG) pillars 
within a weaving channel, with each pillar containing rat liver microsomes enclosed within a 3D 
hydrogel matrix (Figure 1.7). The concentrations of seven different substrates were used to test the 
P450 reaction in a microsome solution within a standard well plate system, ranging from 2μM to 
80μM. Data was extrapolated and a mathematical model of the system based on Michaelis-Menten 
kinetics was produced, showing a high level of agreement between the two. The chip was then 
analyzed and a model was created.  
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Figure 1.7: Engineering methods for the development of liver ultrastructures [103]: A) branched vascular channels developed by 
the silicon micromachining technique. B) An artificial liver sinusoid with an endothelial-like barrier using microfluidic devices 
[99]. C) Development of an in vivo-mimetic microliver tissue using concave microwells and the tri-culture method of three types 
of primary liver cells encapsulated in collagen–alginate composites. D) The decellularization method for obtaining an 
ultrastructure-embedded liver scaffold.  
Chao et al.[104]  published an evaluation of a novel microfluidic device, the HμREL® biochip. 
Four biochips are enclosed in a polycarbonate housing connected, by tubing lines, to a fluid 
reservoir and peristaltic pump. Each biochip has one or more separate compartments in which 
different cells can be housed. The compartments are microfluidically connected, in a linear path, 
to allow for interaction between the cell types. Evaluation of the system using primary human 
hepatocytes indicated the system preserved cell viability and metabolic competency at least as 
high as, and sometimes higher than, the traditional static culture conditions. 
The use of a single cell culture has shown to bring to successful results, but at the same time using 
multiple cells in a liver-on-a-chip model, has the potential for even more realistic in vitro results, 
since liver has a complex structure composed of multiple cells in interaction with each other. 
An example of co-culture on a chip was developed by Schütte et al. [105], where a co-culture of 
primary human hepatocytes and endothelial cells was used to recreate a 3D sinusoidal-like 
structure by dielectrophoresis (DEP).    
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Lee at al. [106] employed a spheroid-based microfluidic chip, for the development of the 3D in 
vitro model of ALD progression (Figure 1.8 B). They co-cultured rat primary hepatocytes and 
hepatic stellate cells (HSCs) in a fluidic chip to investigate the role of HSCs in the recovery of 
liver with ALD. An interstitial level of flow derived by an osmotic pump was applied to the chip 
to provide in vivo mimicking of fluid activity. Using this in vitro tool, it was observed structural 
changes and decreased hepatic functions with the increase in ethanol concentration. The recovery 
process of liver injured by alcohol was observed by providing fresh culture medium to the 
damaged 3D liver tissue for few days. A reversibly- and irreversibly-injured ALD model was 
established.  Other example of co-culture on chip is represented by the fabrication of spheroids of 
HSCs and hepatocytes maintained in microfluidic systems, [107] exhibited improved albumin 
secretion and stained positive for CYP450 reductase, in contrast to their monocellular controls.  
Also, to investigate and consider the mutual effects of various organs on their drug toxicity, co-
cultured organ models on a chip have also been introduced. 
Multi-organ device was created by Wagner et al. [108], which combined a microfluidic channels 
system with separated tissue compartments, liver microtissues (HepaRG and HHSteC) and skin 
biopsies. This system allowed the crosstalk between the different organs in order to assess the 
metabolic state of the cells during culture time. It also can facilitate the effective drug screening 
considering diverse pharmacodynamic parameters through organ–organ interaction.  
 
Figure 1.8: The application of microtechnology-based liver systems in drug screening and toxicity testing [103]: A) the 3D 
HepaTox Chip with microchannels in 2D and 3D co-culture systems for in vitro toxicity test. B) A 3D-based liver-on-a-chip 
system of hepatic microtissues and hepatic stellate cells with interstitial flow [107]. 
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 Gut-on chip 1.5
 
Microfluidic systems can be used to reproduce the dynamic microenvironment in the intestine 
which is characterized by peristaltic motions and intraluminal fluid flow. Recently, microporous 
SU-8 membranes were fabricated with 3D villus-like features, with the goal of incorporating a 
more relevant 3D intestinal microenvironment into the mCCA system [109] (Figure 1.9A). 
Long-term perfusion culture of Caco-2 cells on track etched membranes was demonstrated in a 
microfluidic device with integrated micro-pumps and on-chip optical fibre sensors [110].  
Kim et al reported a human gut-on-a-chip device that include peristalsis, fluid flow, and microbial 
flora [111] (Figure 1.9). Compared to static culture, cells cultured on the device exhibited 
accelerated intestinal epithelial cell differentiation, formation of villi-like structures and increased 
intestinal barrier functions. This finding challenged the traditional understanding that Caco-2 cells 
only differentiate into enterocyte cell types under normal culture conditions. Mucus production 
and CYP3A4 enzyme activity, which are usually missing in Caco-2 monolayers, were also 
detected under the dynamic culture condition without any drug inductions. However, the level of 
CYP3A4 activity was about three orders of magnitude lower than that reported for human small 
intestine. The aforementioned models are mostly characterized 2D culture over a porous 
membrane which can be organized in a 3D fashion. Integration of 3D tissues in a microfluidic 
device could be better reproduce the in vivo interaction with ECM under dynamic conditions.  
 
Figure 1.9: a) Caco-2 cells grown on microporous SU-8 membranes [109] Cells were stained for actin (green) and nucleic acid 
(blue). (b) A schematic of the gut-on-a-chip device [111]. (c) Vertical cross section of villous-like structures [60]. Cells were 
stained for actin (green), nucleic acid (blue) and Muc2 (magenta). (d–g) Single Lgr5+ stem-cell-derived organoids were stained for 
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villin [(d): green, enterocytes), Muc2 (e): red, goblet cells], lysozyme (f): green, Paneth cells], chromogranin A [(g): green, 
enteroendocrine cells] and nucleic acid (blue) [112].  
 
 
 First-pass metabolism in vitro model 1.6
To predict the drug bioavailability and toxicity in vivo in an accurate and predictive manner, it is 
essential to model the enterohepatic circulation and first-pass metabolism. In vitro models of the 
liver and GI have been developed individually, but the single-organ systems lack the complex 
intercellular and inter-organ communication that occurs in vivo and therefore are unable to 
properly model first-pass metabolism and bile acid regulation that has been shown to be critical 
for assessing drug metabolism. In an attempt to recapitulate the integration of the GI tract and the 
liver, several in vitro models have been established. About static integrated model, Choi et al. first  
[113] developed a static integrated Caco-2/HepG2 system to study toxicity. In this model a 
transwell insert was used to seed Caco-2 on the apical side and HepG2 on the basal side of the 
polycarbonate membrane, in order to mimic the sequence of oral absorption and metabolism of 
xenobiotics in vivo. This type of co-culture enhance the CYP1A2 activity and increase sensitivity 
when a drug was used to treat the system. Similar models have been used to investigate first-pass 
metabolism, bioavailability, and toxicity of pharmaceuticals undergoing clinical trials.  
 Microfluidic model of first-pass metabolism 1.7
 
First-pass elimination takes place when a drug is metabolized between its site of administration 
and the site of sampling for measurement of drug concentration. Clinically, first-pass metabolism 
is important when the fraction of the dose administered that escapes metabolism is small and 
variable. In an attempt to model the dynamic nature of first-pass metabolism, several models have 
been developed incorporating intestinal and hepatic models in fluidic systems to monitor drug 
transport, metabolism and toxicity. In a microfluidic model in which fluid flow is present, 
metabolites are transported from the GI-tract cells to the liver cells located downstream. Mahler et 
al. developed a microfluidic biochip in which HT-29 goblet-like cells are included in the GI-tract 
compartment so that the Caco-2 cell layer was covered with mucous. The model responded to a 
challenge involving acetaminophen with liver cell toxicity in a dose-dependent manner, and 
acetaminophen metabolites were detected in the medium. Acetaminophen is a widely used 
analgesic and antipyretic drug that can cause hepatotoxicity when taken at an overdose. It is a 
small, non-ionized molecule that passively diffuses across the GI-tract epithelium. The presence 
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of the GI-tract barrier in the micro cell culture model reduced liver cell death because 
acetaminophen diffused slowly across the mucous-covered Caco-2/HT-29 cell layer, and, in 
addition, intestinal cells also converted some of the drug into nontoxic metabolites [114]. The 
result obtained with the first-pass metabolism model was consistent with those obtained with 
acetaminophen challenges in mice [115]. Prot et al. developed instead a polycarbonate bioreactor 
where the Caco-2 cells were cultivated on a conventional cell culture insert. The insert was then 
incorporated into a dedicated fluidic platform that could be coupled with a microfluidic biochip 
which is cultivated with HepG2/C3a, freshly isolated rat primary hepatocytes and human 
cryopreserved hepatocytes, for comparative purposes. First-pass intestinal absorption and liver 
metabolism were studied using phenacetin. In addition, a mathematical model was built based on 
the experimental data. The corresponding PK model was used to estimate the kinetic parameters 
describing the transfer of the molecule across the intestinal barrier, as well as intestinal and 
hepatic clearances. Finally organ mathematical models were used to predict situations in humans 
[116]. Midwoud et al. designed a microfluidic system for the purpose of investigating inter-organ 
effects, made by coupling two microchambers, one containing an intestinal tissue slice, the other a 
liver slice, which can be sequentially perfused. In this way, metabolites formed by the intestine in 
the first chamber can be directed to the liver in the second chamber for further metabolism, 
thereby mimicking in vivo, first-pass metabolism. In addition, the possible influence of 
metabolites or other mediators formed by the intestine on the liver can be studied, providing 
insight into interorgan effects [117]. 
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Chapter 2  
2 A novel three dimensional hepatic model 
on chip: functionality study and  
xenobiotic toxicity assessment 
 Introduction 2.1
 
During the last 20 years, progress in pharmaceutical industry has revolutionized the field of drug 
discovery, producing an elevated number of new compounds. In vivo animal tests provide 
complete data sets on the absorption, distribution, metabolism, and excretion (ADME) parameters 
for a given molecule. Nevertheless, in vivo studies performed with laboratory animals do not 
predict human responses exactly. They are also expensive, time-consuming, and can be considered 
as unethical. On the other hand, in vitro experiments cannot easily reproduce the organ to organ 
interactions and thus poorly mimic the ADME process. For these reasons, the actual drug 
development process is affected by a high rate of failure during clinical trials, which is due to the 
lack of an appropriate in vivo and in vitro model to predict the effect of a drug. There is the need 
to develop more predictive platforms that can better reproduce the human in vivo environment and 
can complement the existing models. Liver plays a fundamental role in drug metabolism and body 
detoxification from xenobiotics compounds. Xenobiotics induced hepatotoxicity is one of the 
main reasons for drug withdrawal thus imply the need of the development of robust in vitro model 
for evaluate hepatotoxicity. Conventional hepatic model are based on 2D mono- and co-cultures 
of primary hepatocytes. These model cannot reproduce the complex 3D microenvironment and 
extracellular matrix support. For these reason, primary hepatocytes shows rapid loss of their 
phenotype, resulting in downregulation of their metabolic biomarker. To overcome this 
limitations, efforts are focused on the developing of new 3D models that can mimic the cell-cell 
and cell-ECM interactions. Among various 3D liver culture models, hepatic spheroids which 
formed by aggregation of cells, have been the focus of a number of studies. However, spheroids 
involve in the formation of a necrotic core as spheroids size increase limiting their use for long-
term culture [118]. Recently, Matsunaga et al. seeded HepG2 cells onto collagen gel microbeads, 
assembled them in a construct with a doll-like shape, which however was only several millimeters 
in size.  Moreover, these authors illustrated the co-culture of HepG2 cells with NIH 3T3 cells in 
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this system, conferring the possibility of engineering complex tissues [119]. Other important 
studies based on cell and microcarrier approach was develop by Brancato et al. where it was carry 
out a comparison between two different kind of 3D cancer model, spheroids and microtissues, in 
order to evaluate the best micromodules type that reproduce tumor microenvironment [120]. 
However, since the in vivo microenvironment is dynamic, it is fundamental for drug toxicity 
studies to use dynamic models, which provide appropriate mass-transport for gas and metabolite 
waste. With the rapid advancements in microfabrication technologies it have been possible to 
create new platforms that mimic the in vivo dynamic conditions. For this purpose, Ho et al. 
developed a microfluidic device seeded with a co-culture of hepatocytes and endothelial cells to 
recreate the in vivo physiology of liver lobule [121]. Giobbe et al. have derived functional tissue-
specific cells via hPSC differentiation directly on a chip through a robust multistage microfluidic 
technology, and demonstrate the derivation of functional hepatocyte-like cells that may prove 
suitable for high-throughput drug testing [122]. However, hepatic models based on 2D mono- or 
co-culture of human cells are not suitable to reproduce the 3D architecture and extracellular 
matrix, leading to a poor predictive platform for drug screening process. For this purpose, the 
combination of 3D tissue model and microfluidic systems can improve the tissue specific 
functions mimicking the in vivo environment with blood flow suppling oxygen and nutrients. One 
example of this approach is represented by the microfluidic culture of liver tissue slice developed 
by van Midwoud et al. [123]. Using tissue slice may represents a valid 3D model but it is difficult 
to obtain healthy hepatic biopsies not to mention that they lost viability in few days in vitro and 
are not suitable for high-throughput studies. For this purpose, in our recent studies we design a 
perfusion bioreactor for on-line investigation of ECM remodeling. Coupling engineered 3D 
dermal engineered tissue in a microfluidic it have been possible to evaluate the cellular and 
extracellular behavior [124]. The same approach, a microfluidic platform was presented to study 
the interactions between normal and cancer cells [125].  
In this study we describe the design and fabrication of a 3D liver-on-chip system that enables cell 
culture under continuous fluid flow and mimic the liver sinusoid. In vivo, the hepatic sinusoid is a 
microfluidic system that carries blood from the hepatic artery and portal vein, exposing the liver to 
oxygen and nutrients; this blood supply can also expose the liver to toxins and infectious agents. 
To achieve this, we first compare two different 3D hepatic tissue, HepG2- μTPs and HepG2-
spheroids in terms of morphology and functionality and then develop a microfluidic device that 
could resemble the hepatic sinusoid. With  the aim to produce a model for predictive drug toxicity 
comparable with in vivo conditions, three-dimensional liver HepG2- μTPs were selected to be 
cultured into the biochip with different ethanol concentration to tests alcoholic effects. Viability 
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assessment through cell auto-fluorescence coupled with two-photon microscopy allows on-line 
monitoring of ethanol toxicity without using dyes in a non-invasive manner.  
 
 Materials and Methods 2.2
 Cell type 2.2.1
HepG2 were provided by American Type Culture Collection (ATCC). Cells were sub-cultured 
onto 150 mm Petri dishes in Minimum Essential Medium Earle’s Salt (Microtech) containing 10% 
fetal bovine serum, 100 μg mL−1 L-glutamine, 100 U mL−1 penicillin/streptomycin,  0.1 mM Non 
Essential Amino Acid and 0.1 mM Sodium pyruvate. Cells were maintained at 37 °C in a 
humidified atmosphere containing 5% CO2.  
 Microscaffold production 2.2.2
Gelatin porous microbeads (GPMs) have been prepared according to a modified double emulsion 
protocol (O/W/O). Gelatin (type B, Sigma Aldrich Chemical Company, Bloom 225, Mw = l76 
654 Dalton) was dissolved into 10 ml of water containing TWEEN 85 (6% w/v) (Sigma Aldrich 
Chemical Company). Toluene containing SPAN 85 (3% w/v) (Sigma Aldrich Chemical 
Company) was continuously added to the aqueous gelatin solution (8% w/v) to obtain primary oil 
in water emulsion. Gelatin’s beads containing droplets of toluene were made through the addition 
of excess toluene in order to have a double emulsion (O/W/O). The resulting microspheres were 
dried at room temperature and selected in the range of 75–150 μm in diameter by using 
commercial sieves (Sieves IG/3-EXP, Retsch). GPMs have been stabilized by crosslink reaction 
with glyceraldehydes (GAL), in order to make them stable in aqueous environment at 37 °C, as 
previously described. GAL at 4% w/w of the microbeads has been used to perform all the 
experiments. Before their use, dry GPM were sterilized with ethanol 100% for 24h then washed 
three times in PBS. Before cell seeding PBS was removed and replaced with culture medium 
[126]. 
 HepG2-Microtissues production  2.2.3
All cell cultures on microscaffolds were performed in spinner flask (Integra). Briefly, 35 mg of 
GPMs were loaded with 5,25 × 106cells (30 cell/GMP ratio). To promote cell seeding on GMPs 
an intermittent stirring regime (30 min at 0 rpm, 5 min at 30 rpm) for 24 h. After seeding, the 
stirring speed was kept at a continuous 30 rpm for up to 14 days. Culture medium were changed 
every two days. All cultures were maintained at 37 °C in a humidified 5% CO2 incubator. The 
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HepG2 microtissues precursors obtained (HepG2-µTPs) samples were taken for further 
investigations at days 3, 5, 7, 10 and 14 and fixed for further investigations. 
 
 HepG2-Spheroid formation 2.2.4
Cells grown as a monolayer were trypsinized to generate a single-cell suspension. The cell 
suspension was diluted to 1,5 × 104  cells per milliliter in EMEM supplemented with 20% of 
0.24% methyl cellulose and seeded onto round bottom non-tissue culture treated 96 well-plates 
(Falcon, BD NJ,USA) in order to have 3000 cells/well. For preparation of methylcellulose stock 
solution 3 g of methylcellulose powder (M0512, Sigma-Aldrich) was autoclaved  in a 250 ml 
bottle containing a magnetic stirrer. The autoclaved methylcellulose was dissolved in preheated 
125 ml EMEM at 60 °C for 20 min by using the magnetic stirrer. Thereafter, 125 ml medium (RT) 
containing double amount of FBS (20%) was added to a final volume of 250 ml and the whole 
solution mixed overnight at 4 °C. The final stock solution was aliquoted and cleared by 
centrifugation (5000 g, 2 h, RT). Only the clear highly viscous supernatant was used for the 
spheroid assay (about 90 - 95% of the stock solution). Spheroids were grown under standard 
culture conditions (5% CO2 at 37 °C) and fixed at days 3, 5, 7, 10 and 14 for further 
investigations. 
 Cell viability  2.2.5
At the day 3, 5, 7,10 and 14 of culture, 200 μL aliquots were collected from the spinner flask to 
assess the viability of the µTPs. Then aliquots were transferred to a cell culture dish (w/2 mm grid 
Nunc) for microcarriers counting, then the microcarriers suspension was placed in a new 2 ml tube 
and washed twice with PBS. To detach cells from microcarriers, µTPs were incubated with trypsin 
for 5 min. The detached cells were stained with Trypan Blue to assess viability of the cells over 
the microbeads. For Trypan blue staining,  200 μL of cells suspension was transferred to a 1,5-mL 
clear Eppendorf tube and incubated for 3 min at RT with 300 μL of PBS and 500 μL of 0,4% 
Trypan Blue solution (Sigma-Aldrich). Cells were counted using dual chamber hemocytometer 
and a light microscope. Viable and non-viable cells were recorded separately, and the means of 
three independent cells counts were pooled to obtain a percentage of viability. In the same way, a 
96-well plate of HepG2-spheroids were trypsin digested for each time point in order to evaluate 
cell viability. 
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 Histological and immunohistochemical analysis 2.2.6
1 mL aliquots of HepG2-µTPs or HepG2-spheroids at day 3, 5, 7,10 and 14 were fixed in a 
solution of 10% neutral buffered formalin for 1 h, rinsed in PBS, dehydrated in an incremental 
series of alcohol (75%,85%, 95% and 100% twice, each step 30 min at RT), then treated with 
xylene (30 min twice) and embedded in paraffin. Tissue  sections,  5 µm  thick,  were  stained  
with  hematoxylin  and  eosin (H&E), mounted  with  Histomount mounting  solution  (Bioptica)  
on  coverslips  and  the  morphological  features  of  3D  tissues  were observed  with  a  light  
microscope. For immunohistochemical staining (IHC) of anti-human Caspase-3, A mouse and 
rabbit specific HRP/DAB (ABC) detection kit (Abcam, UK) was used according to the 
manufacturer’s protocol. 
 Diameter evaluation of micromodules 2.2.7
To evaluate the diameter variation of HepG2-µTPs or HepG2-spheroids, 1 mL aliquots were 
collected at different time point (3, 5, 7,10 and 14 days) and placed under microscope (Olympus 
CK X41) in order to obtain at least 100 images of spheroids and µTPs for each time point. The 
acquired images were processed using Image J software. After binary transformation and 
thresholding of the initial images, the areas distribution of both HepG2-µTPs and HepG2-
spheroids was evaluated by using the tool “Analyze Particles”. From the areas distribution, we 
estimate the diameter for all samples at each time point. Values were reported as mean ± standard 
deviation. 
 Immunofluorescence analysis 2.2.8
 For immunofluorescence staining of HepG2-µTPs or HepG2-spheroids, deparaffinized and 
reyhdrated 5 µm thick tissue sections were heat-induced epitope retrieval in sodium citrate buffer 
at pH 6.0 for 5 min at  97  °C  followed  by  10  min  at  70  °C in  uncloaking  chamber,  washed  
with  PBS  containing  0.2% Triton X-100, blocked with 6% BSA, 5% FBS solution  for 1h at RT, 
and incubated with rabbit anti-human P-gp (dilution 1/100) (Abcam UK) overnight at 4 °C. Then, 
secondary antibody incubation (Alexa Fluor 488) was performed, cell nuclei were detected by 
DAPI staining (5 µm/mL, Sigma Aldrich).  
 Albumin and Urea measurement  2.2.9
At each time point  (3, 5, 7, 10 and 14 days) HepG2-µTPs or HepG2-spheroids’ supernatants were 
collected from the spinner flask and from 96 well-plates respectively, in order to measure albumin 
and urea released by HepG2 cells. Once collected, the supernatants were centrifuged at 2000 g for 
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10 min in order to remove the cell debris. The supernatants were stored at -20 °C before being 
analysed. Albumin secretion in cell culture supernatants quantified by a sandwich enzyme-linked 
immunosorbent assay (ELISA)  kit (Abcam ab179887) according to the manufacturer’s protocol. 
Briefly, albumin specific antibody has been pre-coated onto 96-well plates and blocked. 50 μL of 
samples were added to the wells and subsequently albumin specific biotinylated detection 
antibody was added and then followed by washing with wash buffer. Streptavidin Peroxidase 
Complex was added and unbound conjugates were washed away with wash buffer. TMB was then 
used to visualize Streptavidin Peroxidase enzymatic reaction. TMB was catalysed by Streptavidin 
Peroxidase to produce a blue colour product that changes into yellow after adding acidic stop 
solution. Then the absorbance of individual well was measured at 450 nm by a microplate reader 
(Enspire Multimode Plate Reader PerkinElmer). All experiments were done in triplicates. The 
density of yellow colouration was directly proportional to the amount of albumin captured in 
plate. Urea levels of cell supernatants were determined by Quanti Chrom TM Urea Assay Kit 
(DIUR-500) according to the manufacturer's instruction. Briefly, 50 μL of samples are added to 
the wells and then 200 μL of working reagent, incubate for 50 min. The intensity of the colour, 
measured at 430nm using a microplate reader, was directly proportional to the urea concentration 
in the sample. The concentration of these biomarker was used to calculate the secretion rates 
(pg/h) of the four biomarkers during the 24 h period normalized for viable cells.  
 Microdevice fabrication  2.2.10
The microfluidic Liver-on-chip device used in this work, was fabricated by a rapid prototyping 
procedure. The microfluidic device was prepared by demolding polydimethylsiloxane (PDMS) 
(Sylgard 184, Mascherpa), from a Poly(methyl methacrylate) (PMMA, Goodfellow) slab. The 
PMMA master mold was designed by AutoCAD and carved with micromilling machine 
(Minithech CNC Mini-Mill) making a relief positive geometry in order to avoid silanization 
process of PDMS. The central microchannel (0.5 mm wide, 0.3 mm high) was separated from 
three parallels tissue chamber (0.5 mm wide, 0.3 mm high, 1 mm long) by small pillars (0.100 mm 
diameter, 0.09 mm pillar interspace). The ratio of PDMS pre-polymer and curing agent was 10:1 
(w/w), then the mixture was degassed under vacuum for 20 min to remove air bubbles and then 
poured on PMMA masters. The set-up was incubated at 80 °C for 60 min, then peeled off from 
master moulds. Inlet and outlet holes were punched with a 2.5 mm biopsy punch (DifaCooper). 
The device was bonded to a glass coverslips (24 mm wide × 60 mm long) by oxygen plasma 
treatment for 1 min at 50 W in an oxygen plasma oven (Plasma Femto, Diener).  Subsequently, 
the whole setup was incubated at 80 ºC overnight to achieve irreversible bonding of the PDMS 
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and the glass. Before tissue culture, liver-on-chip microdevice, tubes and connectors were 
sterilized by autoclaving. Tygon tubes were inserted into the inlets and outlets of the central 
channel using male luer lock connectors (Harvard Apparatus), then, the microtissues were placed 
into the liver chambers by pipetting. Furthermore, the whole setup was connected to syringe pump 
(Harvard Apparatus) in order to obtain a flow rate of 5 μl min−1. Finally, the liver-on-chip 
microdevice was placed at 37 ºC in a humidified incubator under 5% CO2 in air.  
 
 Perfusion culture and ethanol injury 2.2.11
The HepG2-µTPs were collected from the spinner flask, in a time range from day 5 to day 7, and 
were inoculated into the three chambers of the liver-on-chip device through the inlet µTPs by 
pipetting. During the filling steps, all the inlet and outlet channels were left open to allow fluid 
escape. For the creation of the ethanol injury, medium containing different concentrations of 
ethanol was applied to HepG2-µTPs and they were cultured for 2 and 4 days.  In each experiment 
three different devices were perfused, one for the control group and two with different ethanol 
concentrations, 100mM and 300mM. The culture media supernatants from each devices were 
collected for the evaluation of albumin, urea and LDH release at each time point. Culture media 
supernatants accumulated in the reservoir was collected and stored at -20 °C before being 
analyzed. Then albumin and urea measurement were performed as reported in Par. 2.2.9. LDH 
activity was performed, using Lactate Dehydrogenase Activity Assay Kit (Sigma Aldrich) 
according to the  manufacturer's protocol. Briefly, 50 μL of sample or NADH standard were added 
to a well of a 96-well microtiter. Then reaction mix was added to each well and after 2-5 min the 
absorbance at 450 nm was measured using a microplate reader, in this way a 𝑇𝑖𝑛𝑖𝑡𝑖𝑎𝑙 was fixed. 
Subsequent measurement were lead every 5 min until the value of the most active sample is 
greater than the value of the highest standard, the time of the penultimate reading is 𝑇𝑓𝑖𝑛𝑎𝑙 . The 
LDH activity was evaluated by the following equation: 
𝐿𝐷𝐻 =
𝐵 × 𝑆𝑎𝑚𝑝𝑙𝑒 𝑑𝑖𝑙𝑢𝑖𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟
𝑅𝑒𝑎𝑐𝑡𝑖𝑜𝑛 𝑡𝑖𝑚𝑒 × 𝑉
 
Where B is the amount (nmole) of NADH generated between 𝑇𝑖𝑛𝑖𝑡𝑖𝑎𝑙  and 𝑇𝑓𝑖𝑛𝑎𝑙 , reaction time is 
the difference between 𝑇𝑓𝑖𝑛𝑎𝑙 and 𝑇𝑖𝑛𝑖𝑡𝑖𝑎𝑙  , and V is the sample volume.  
 
 On line cell viability: Cell auto-fluorescence  2.2.12
Live and dead cells emission spectra were obtained by the following procedure [127]. Firstly we 
used 2D cells culture as a proof of the technique. To prepare live cells, HepG2 were seeded onto a 
Fluorodish and placed in a at 37 ºC in a humidified incubator under 5% CO2 in air. To prepare 
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dead cells, HepG2 were detached using trypsin and suspended in PBS then 1 mL of  HCl 1N was 
added to 9 mL of cell suspension for 10 min at RT. Then by mixing known amounts of living 
cells, we obtained different fraction of living cells (𝛼): 100%, 75%, 50%, 25% and 0%. Cells and 
HepG2-µTPs images  were acquired on a Leica TCS SP5 coupled with a Multiphoton Microscope 
stage (Chamaleon Compact OPO-Vis Coherent) with a 25X/1.25 NA objective.  
The excitation light source was tuned to an excitation wavelength 𝜆ex = 730 nm. Spectral images 
were obtained by separation of the emitted auto-fluorescence into 19 wavelength bands from 400 
to 608 nm with a step of 10 nm. Then, by using microscope internal software, characteristic 
emission spectra of 100% and 0% live cells were generated from spectral images. In order to 
evaluate the cell viability of the HepG2-µTPs into the liver-on-chip device, two-photon images of 
the biochips were acquired by placing the device chamber on the multiphoton stage. HepG2-µTPs 
viability was measured for control and treated samples at days 2 and 4. In order to exclude the 
signal rising from the microbeads, specific ROI were chosen to obtain emission spectra on the 
spectral images. Analysis were performed on 100 images, and the resultant spectra were 
normalized to the highest intensity value. Emission spectra data was post-processed to obtain 
means and standard deviation of the collected spectral curves, in particular the emission spectra 
corresponding to 100% and 0% live cells, were fitted with a 3
th
 order polynomial function (𝑃) 
bringing to 𝑃100 e 𝑃0. To get viability information from liver-on-chip devices (control and treated 
groups), the polynomial (Px) corresponding to an emission spectra from an unknown cell fraction 
(𝛼𝑥), was considered as a linear function of 𝑃100 and 𝑃0 as reported in Eq 1.  
 𝑃𝑥 = 𝛼𝑥𝑃100 + (1 − 𝛼𝑥)𝑃0        (1) 
Where 𝑃𝑥  is the polynomial function of the unknown cell fraction spectrum, 𝑃100 and 𝑃0 are the 
polynomial functions of the spectra of known cell fractions 𝛼 = 100% and at 𝛼 = 0, 𝛼𝑥  is the 
unknown cell fraction. This operation was performed by means of a custom-written MATLAB. In 
order to validate the effectiveness of this procedure, we inserted in the equation 1 the spectra 
obtained by known cell fraction, 25%, 50% and 75%.  
 Analysis of oxidative stress 2.2.13
Oxidative stress was measured by assessing intracellular ROS levels generated after exposure for 
2 days and 4 days with ethanol, through the green-fluorescent ROS detection reagent 6-carboxy-
2′,7′-dichlorodihydrofluorescein diacetate, di(acetoxymethyl ester) (carboxy-H2DCFDA, Thermo 
Fisher Scientific), according to the manufacturer’s instructions. Briefly, liver-on-chip devices 
were rinsed in PBS and loaded with 10 μM of the cell-permeant probe carboxy-H2DCFDA for 30 
min at 37°C in PBS solution to exclude hydrogen peroxide generation in phenol red containing 
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medium, before fluorescence analysis. Incubation with 400 μM H2O2 (Sigma-Aldrich) was used as 
a positive control for ROS. FITC images were acquired on a Leica TCS SP5 coupled with a 
Multiphoton Microscope stage (Chamaleon Compact OPO-Vis Coherent) with a 25X/1.25 NA 
objective. 
 Statistical analysis 2.2.14
Data are expressed, as mean ± standard deviation and show the results from three independent 
experiments. The differences between two or more groups were evaluated (p value < 0.05) using 
one-way analysis of variance (ANOVA). A Gaussian distribution for each population was 
assumed. For pair-wise comparisons within each experimental group, Tukey’s post-test was used. 
 
 Results 2.3
 Time evolution of viability and morphology of µTPs and 2.3.1
spheroid model 
Two types of 3D tissue models were fabricated and compared, HepG2-µTPs and HepG2-
spheroids. Viability of both samples was evaluated by Trypan Blue assay during 14 days of 
culture. In Figure 2.1 was reported the cell viability for HepG2-µTPs and HepG2-spheroids at day 
3, 5, 7, 10 and 14.  The HepG2-µTPs exhibited a cell viability maintained between 95% and 85% 
till day 10, with a little decrease to 73% ± 7.085% at day 14. As reported in the graph (Figure 2.1), 
from day 5 µTPs shows higher viability then spheroids for all the time of the culture. In particular 
at day 7 the viability of the HepG2-spheroid (70% ± 15,631%) corresponded to the viability of 
HepG2-µTPs at day 14, indicating a rapid decrease of HepG2-spheroids viability already at day 7.  
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Figure 2.1: Cell viability assessment of µTPs and spheroids at day 3, 5, 7, 10, 14. Asterisks indicates statistical difference p< 0.05 
 
The bright field images of the HepG2-µTPs (Figure 2.2 A-E) highlighted that during the spinner 
culture time, the HepG2-µTPs from day 5 increased their size starting to aggregate in more large 
constructs. Instead, the HepG2-spheroids started already from a larger size, then they exhibited 
only a little increment of their size (Figure 2.2 F-J). 
 
 
Figure 2.2: Bright field images of HepG2 µTPs (A-E) and HepG2 spheroids (F-J) at day 3, 5, 7, 10 and 14. Scale bar is 200 µm 
 
In Figure 2.3 was reported the diameter variation during culture time for both HepG2-µTPs (A) 
and HepG2-spheroids (B) models. Starting from day 3, the diameter variation was evaluated by 
Image J software using “Analyze Particles” tool. As reported in the graph (Figure 2.3), the µTPs 
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showed a progressive increasing of the diameter corresponding to the fusion capability of the 
micromodules, the spheroids’size instead was almost the same during all culture time. To evaluate 
the morphological features of the HepG2-µTPs and HepG2-spheroids, histological analysis were 
performed. The HepG2-µTPs and HepG2-spheroids were stained with Hematoxylin and Eosin at 
day 3, 5, 7, 10, 14, as shown in Figure 2.4 . The H&E staining of HepG2-µTPs showed the cells 
distribution over the microbeads surface (Figure 2.4 A-E) demonstrating typical liver histotypic 
features such as a cuboidal hepatocyte cell shape with tight cell-cell contacts. These features were 
preserved over the tested culture period. For the HepG2-spheroid model, the latter features were 
also expressed but there was the presence of a necrotic core started from day 7 (Figure 2.4 F-J) 
which suggests that the quantity of oxygen and other nutrients transported into the inner regions of 
the spheroids, was not sufficient. This was confirmed by immunohistochemistry of Caspase-3 
(Figure 2.5) of HepG2-µTPs (Figure 2.5 A-C) and HepG2-spheroids (Figure 2.5 D-F). The images 
shows that spheroids are in apoptotic phase since only low signal is present in µTPs. 
 
 
 
Figure 2.3: Diameter variation of HepG2-µTPs and HepG2-spheroids during culture time. Asterisks indicate statistical difference 
with p<0.05 
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Figure 2.4: Hematoxylin and eosin images of HepG2-µTPs(A-E) and HepG2-spheroids (F-J) at Day 3,5,7,10 and 14. Scale bar 100 
µm. 
 
 
Figure 2.5: Immunohistochemical analysis of Caspase 3 for HepG2-µTPs(A-C) and HepG2-spheroids (D-F) at Day 3,5,7,10 and 
14. Scale bar 100 µm. 
 Functional assessment of HepG2-µTPs and HepG2-spheroids 2.3.2
The functions of HepG2-µTPs and HepG2-spheroids were evaluated by measuring albumin and 
urea synthesis which are typical functions of liver cells, at different time point: day 3, 5, 7, 10, 14. 
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By collecting  HepG2-µTPs or HepG2-spheroids supernatants, albumin and urea production were 
quantified by ELISA and colorimetric assay respectively.   
 
Figure 2.6: Albumin (A) and Urea production rate  (B) of µTPs and spheroids during 14 days of culture.  Asterisks indicate 
statistical difference with p<0.05 
 
As shown in Figure 2.6 the spinner culture was able to sustain the biomarkers production during 
culture time better than static spheroid culture. The albumin production (Figure 2.6-A) was 0.0175 
± 0.0027 pg/h/cell at day 3, at day 7 it reached the maximum value of 0.0182 ± 0.0017 pg/h/cell 
and decrease to 0.0157 ± 0.004 pg/h/cell. For the HepG2-spheroids, albumin production had the 
same trend but with lower values (Figure 2.6-B). 
To assess cell polarization of both 3D model P-gp were analysed via immunofluorescence. The P-
gp expression in HepG2-µTPs (Figure 2.7) and HepG2- spheroids (Figure 2.8) detected over 14 
days of culture. In Figure 2.7 A-C the immunofluorescence staining shows that the P-gp 
expression was higher in HepG2-µTPs than in spheroids (Figure 2.8 A-C) where only few pixel 
were detected. In Figure 2.9 was shown a three dimensional reconstruction of 
immunofluorescence staining of P-gp in both HepG2-µTPs and HepG2-spheroids. In this images 
an higher expression of the protein is visible in the microtissues models.  
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Figure 2.7: Immunofluorescence staining of P-Glycoprotein (green) and nuclei (DAPI, blue) in µTPs at day 5, day 10 
and day 14. Scale bar 100 μm. 
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Figure 2.8: Immunofluorescence staining of P-Glycoprotein (green) and nuclei (DAPI, blue) in spheroid at day 5, day 10 and day 
14. Scale bar 100 μm. 
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Figure 2.9: 3D reconstruction of immunofluorescence images of P-Glycoprotein (green) and nuclei (DAPI, blue) in HepG2- μTPs 
(A) and HepG2- spheroid at day 7 (B). Scale bar 100 μm. 
 
 Liver-on-chip bioreactor 2.3.3
 
We developed a microfluidic device to replicate the liver sinusoid structure. The Figure 2.10-A 
shows the entire experimental set-up connected to a syringe pump and a reservoir in order to have 
a fluid flow condition and to collect the tissues supernatants respectively. The Figure 2.10 B-C 
shows the geometrical configuration of the biochip, composed by a central channel that perfuse 
three parallel compartments which are connected to it by small pillars. The HepG2-µTPs were 
loaded into the device by pipetting using the three appropriate inlet. The bioreactor system was 
perfused with a flow rate of 5 µL/min.   
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Figure 2.10: Schematic representation of the microfluidic device.  (A) Experimental set-up of the biochip connected to a syringe 
pump and a reservoir. Top view of the design of the biochip (B), three parallel tissues chamber are separated by a medium channel 
by small pillars. (C) Liver-on-chip device photograph filled with food colouring.  
 
 Ethanol cytotoxicity assessment under perfusion culture  2.3.4
Alcoholic injury was investigated by exposing HepG2- µTPs into the biochip to two different 
ethanol concentrations, 100 mM and 300 mM from 2 to 4 days of culture. To assess the ethanol 
cytotoxicity a non-invasive method was used, exploiting cell auto-fluorescence coupled with two 
photon microscopy. The Figure 2.11-A showed the graph of HepG2-µTPs viability into the 
biochip for the control group and for the treated groups with crescent dose of ethanol for a culture 
period of 4 days. Control group devices, maintained the same cell viability during culture time, 
with a value of 66.35 % ± 7.28 % at day 2 and 64.75 % ± 5.08 % at day 4. In contrast, in the 
treated group there is a decrease of the percentage of viability, for 100mM group it was reduced 
from 60.62% ± 14.59% at day 2 and 51.58% ± 0.48% at day 4; for the 300 mM group it declined 
from 41.20% ± 3.68% at day 2 and 19.19% ± 10.45% at day 4. This results were compared with 
LDH release assay, a typical marker of tissues damage. Measurement of LDH activity in the 
 
 
50 
 
eluent showed that cell death in the control group device remained at low levels in the perfusion 
period (day 2 and day 4) in Figure 2.11-B. Exposure to ethanol levels at 300 mM resulted in an 
increase in LDH release compared to the untreated tissue, indicative of increased levels of cell 
death at these concentrations over the time periods assayed. LDH activity at 100 mM showed no 
marked difference compared with the control. 
 
 
Figure 2.11: Ethanol cytotoxicity assessment. (A) Viability on chip evaluated via cell autofluorescence for control group and 
traeted groups. (B) Lactate dehydrogenase (LDH) leakage assay present in the µTPs during perfusion culture in biochip. Asterisks 
indicate statistical difference with p<0.05 
 
 Assessment of hepatic functions 2.3.5
Ethanol toxicity was also performed by measuring hepatic biomarkers albumin and urea 
production. As shown in the graphs (Figure 2.12 A-B) albumin and urea synthesis increased in the 
control group, while the treated group showed a significant decrease of metabolic activity. The 
albumin production (Figure 2.12-A) of the liver-on-chip device was 56.877 ng ± 9.01 ng at day 2 
and 62.723 ng ± 17.418 ad day 4 for the control group. For the ethanol treated groups, albumin 
decreased in a dose dependent manner and over culture time. In particular for 100 mM group, 
albumin production decreased from 19.785 ng ± 8.158 ng at day 2, to 12.657 ng ± 9.8552 ng at 
day 4, for 300 mM group 7.636 ng ± 6.21 ng at day 2 and 0.01985 ng ± 0.0028 ng at day 4. Urea 
synthesis (Figure 2.12-B) of the biochip had the same reduction during culture time. 
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Figure 2.12: Hepatic functions assay: Albumin and urea secretion after 4  days of culture in the perfusion biochip. Asterisks 
indicate statistical difference with p<0.05 
 Analysis of oxidative stress 2.3.6
With the purpose to investigate the oxidative stress caused by ethanol, we evaluated cellular ROS 
levels in liver-on-chip device after 2 days and 4 days (Figure 2.13). ROS levels in control group 
were low after both 2 and 4 days (Figure 2.13 A,D). For 100 mM treated group, at day 2 ROS 
production is similar to the control but after 4 days it increased (Figure 2.13 B,E). The 300 mM 
treated group exhibited the highest ROS production after 4 days of ethanol exposition Figure 2.13 
C, F). The reported low ROS production is in agreement with previous literature reports [128].  
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Figure 2.13: ROS detection assay for the analysis of oxidative stress. Representative images of intracellular ROS produced after 
ethanol treatment at day 2 (A-C) and day 4 (D-F) for control group, 100 mM and 300 mM. Scale bar 100 µm. 
 
 Discussion 2.4
In this work HepG2 cells were used to create two different kind of 3D hepatic tissues model: 
spheroids and microtissues. HepG2-spheroids were obtained by static seeding onto 96 ultra-low 
attachment well plate, while HepG2- µTPs were obtained in a spinner flask bioreactor by dynamic 
cell seeding of HepG2 over gelatin porous microbeads. In a previous work, spheroids and 
microtissues micromodules were compared in order to assess that the µTP model better 
recapitulate the tumor microenvironment and the important differences between normal and 
cancer stroma [120]. In another precedent work, it was demonstrated that fibroblasts under 
microtissues configuration, start to adhere on the microscaffold surface and synthetized extra 
cellular matrix component like collagen, elastin and so on. The authors studied the interactions 
among fibroblasts since microscaffolds triggered mechanotrasduction pathways involved in 
collagen remodelling [126]. In this work we want to compare this two kind of 3D hepatic model in 
order to prove that the final tissues micromodules showed different physiological properties in 
terms of cell proliferation, functional and metabolic activity.  
Differences between HepG2-µTPs and HepG2-spheroids, were detected during 14 days of culture. 
In the spheroid model, size remained almost unchanged and it was higher for all the time of the 
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culture compared to HepG2-µTPs, making spheroids not suitable for the loading into the device. 
Moreover, spheroids with a size over 250 μm shows lower viability and necrotic core [129]. 
About the viability, HepG2-spheroids displayed lower viability than HepG2-µTPs during all the 
time of the culture. In particular still at day 7 they exhibited lower viability then HepG2-µTPs at 
day 14. This results indicate that the spheroid model is not appropriate for long term culture. In 
addition, by histological characterization is evident the presence of necrotic core in HepG2-
spheroids starting from day 7. This data was in agreement with other literature studies reporting 
that cell in the outer layer are proliferative instead cells inside the core are apoptotic and so they 
left the system, in this way the dimension remain constant [130]. We confirm this result by 
immunohistochemical analysis of Caspase-3 both for HepG2-µTPs and HepG2-spheroids in order 
to show apoptotic activity of both model. Indeed, the HepG2-spheroids are positive for Caspase-3 
still from day 7, unlike HepG2-µTPs which showed only little expression of this protein at day 14. 
About hepatic functionalities, the maintenance of the metabolic activity of the hepatic 3D tissues 
model is crucial for their application as drug metabolism studies. However, liver functions of 
primary hepatocytes are rapidly downregulated during their in vitro culture. Although, commercial 
HepG2 cell line express very low metabolic activity compared to primary hepatocytes, they 
provide a stable and easy to handle platform for in vitro studies of hepatotoxicity and they also are 
a valid alternative to primary hepatocytes especially for the use in proof-of-concept studies. For 
this reasons, the developed platform paves the way toward constructs from patient specific 
hepatocytes derived from stem cells, e.g. iPSCs. To assess the hepatic functionalities, we 
quantified the albumin and urea secretion during 14 days of culture. The metabolic activity of 
HepG2-µTPs and HepG2-spheroids had the same decreasing trend during culture time but 
spheroids shows lower secretion levels of these markers.  
The number of cells per HepG2-µTPs and HepG2-spheroids was calculated in order to express the 
albumin and urea concentration in terms of pg/h/cell, to compare the functionalities of the 
developed model with the previous existing platforms. The relative albumin secreted by both 
spheroids and µTPs decreased over time, with a level in a range from 0.2-0.4 pg/cell/day which is 
the same reported in literature for albumin production of HepG2 [131]. The lower secretion of 
metabolic marker from spheroids should be attributed to the decreasing oxygen availability within 
the spheroid core. We further examined the expression pattern of non-secreted proteins by 
immunostaining in both 3D micromodules. One example is P-gp, a protein transporters known to 
be expressed and localized to the canalicular membrane of hepatocytes in vivo. This protein is 
involved in the first-pass effect of xenobiotics and endogenous compounds and exports bio-
transformed chemicals out of the liver. The expression of this transporter was used to confirm the 
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cellular polarization and the formation of bile canaliculi for both HepG2-µTPs and HepG2-
spheroids. Canalicular structures formed from day 10 in the HepG2-µTPs, while only few pixels 
are present in the HepG2-spheroids suggesting lack of expression of P-gp, improper polarization 
or localization, or inactive transporters when cultured in spheroid fashion. Other important aspects 
are the represent by the handling of both HepG2-µTPs and HepG2-spheroids. µTPs were obtained 
in a spinner flask bioreactor so cells and microbeads are added together to the spinner and 
collected from it directly at each time point in a very simple way. This not happened for the 
spheroids because they are cultured in a 96-well plate where they are accommodated one per well. 
In this case, it is difficult to change culture media without the risk of aspirate them. Finally, in 
terms of number of micromodules µTPs have a higher production rate than spheroids using the 
same cell number. Taking account of these results, we believe the using of HepG2-µTPs as 3D 
tissue model would better reproduce the in vivo hepatic metabolic and physiological activity and 
represents a more predictive platform for drug testing. Anyway, 3D static culture lack of 
appropriate mass transport for gas and metabolite waste, which are imperative for drug screening 
studies. A dynamic microenvironment could be achieved by using organ on chip device, which 
could allow heterotypic interaction, low shear stress and the diffusion dominated in vivo like 
environment. Once microtissues was identified as the better three dimensional hepatic in vitro 
model, we load the HepG2-µTPs into the biochip in order to obtain a perfusion culture. With the 
aim to have the better in vitro performance of the HepG2-µTPs, we collected them from day 5 to 
day 7 since they exhibit the higher metabolic activities and viability. In the current report, we 
devised a 3D tissue based in vitro microfluidic model and validate it by applying ethanol-
containing media to HepG2-µTPs. Two different ethanol concentrations were selected, 100 mM 
and 300 mM. Levels over 100 mM ethanol equate to a blood concentration associated with a 
heavy consumer of alcohol.  
Firstly, we investigate the ethanol cytotoxic effect by assess viability. For this purpose, we choose 
a non-invasive method, using cell auto-fluorescence coupled with two photon microscopy. This 
technique was based on the acquisition of the emission spectrum of NADH, a cellular fluorophore 
which plays a central role in cell metabolism. The auto-fluorescence emission of live and dead 
cells was found to be characterized by distinct spectral differences. Using advanced microscopy 
methods, the differences of the spectra of dead and live cells may be exploited to accurately 
differentiate viable from dead cells and assess the cell viability of the HepG2-µTPs.  
The use of conventional methods (e.g. Trypan blue) surely represent the most accurate way to 
assess cell viability but this leads to a discard of the tissue constructs and killing of the cells. 
Multiphoton microscopy can be employed to detect cell viability without using dye or 
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disintegrating the constructs in order to continue the culture or to utilize them for other analysis. 
This method is suitable for those sample that need real time investigation during culture time 
requiring on-line assessment of viability at different time point. Emission spectra extracted from 
confocal images of the biochip were post processed using a custom written MATLAB script in 
order to obtain a percentage of viability of the HepG2-µTPs loaded into the biochip. The viability 
results were in agreement with the ones of LDH activity where is showed that enzyme production 
is higher in the treated samples. Exposure to ethanol levels above 100 mM resulted in an increase 
in LDH release compared to the untreated tissues, indicative of cell death at these concentrations 
over the time period assay. Alcoholic injury cause accumulation of free radicals inside cells. 
Although free radicals from stimulated inflammatory cells may play an important role in alcohol-
dependent liver toxicity, it seems that enhanced intracellular oxidative stress in hepatocytes during 
ethanol exposure limits cell viability [132]. The oxidative stress generated by ethanol treatment 
was assessed by ROS assay. This leads us to prove that acute dose of ethanol causes apoptosis of 
HepG2 cells within bioreactor leading to a decrease of cell viability, increase of LDH release and 
accumulation of ROS species into the cells. About metabolic activity, albumin and urea levels 
steadily increased into the biochip without ethanol treatment, but there is a significant drop in the 
ethanol treated group. This is supported through finding from a previous study using isolated 
perfused liver [12].  
 
 
 Conclusion 2.5
In this work two 3D tissue model were compared in order to identify the model that better 
recapitulate the in vivo physiological and metabolic activity of the liver. Compared to the 
spheroids model, HepG2-μTPs exhibited more viability, higher secretion of biomarker and 
increased polarization and transport capability. Then we developed a liver-on-chip platform that 
enabled maintenance of HepG2-μTPs within the culture chambers of the bioreactor. The 
bioreactor is optical accessible in order to monitor and quantify the cell viability and hepatic 
functionalities, in real time and without discarding the samples. Our system has been proposed as 
a new predictive platform to study cytotoxic effects of xenobiotics compounds, like 
acetaminophen, anti-tumoral drugs, nanoparticles and the hepato-protective effects of 
nutraceuticals. The characteristic geometrical configuration of the chip is also appropriate to 
perform co-culture with others cell time in order to assess the tissues cross-talk. 
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Chapter 3 
3 A microfluidic platform to recreate air-
liquid interface of 3D human intestinal 
equivalent 
 Introduction 3.1
 
In our body, drugs and nutrients are effective only when absorbed by the epithelial intestinal cells. 
Their absorbability, however, changes with the nature of substances involved. To recreate in vitro 
the model of intestinal absorption and metabolism, often are used Caco-2 cells. These cells 
derived from human colonic carcinoma and are a well-known system to mimic intestinal epithelial 
cells. Over two decades ago, several studies of intestinal human in vitro model, were developed by 
culturing Caco-2 on microporous filters [134]. When forming a monolayer under normal culture 
conditions, Caco-2 cells spontaneously differentiate into columnar and polarized cells that have 
similar resistance and permeability as small intestinal enterocytes [134] [135]. Since its 
development, this 2D model has being widely used for permeability testing of new drug 
candidates as well as investigating functionality of different intestinal transporters [136],[137]. 
However, this model lacks physiological relevance in that it fails to capture the 3D 
microenvironment present on the intestinal villi, which has been considered one of the cause for a 
poor correlation between slowly absorbed drugs in vitro and in vivo [138]. For this purpose, 
several studies have been focused on the development of 3D intestinal tissue model. Yu et al. 
presented a novel method to perform drug permeability test by using 3D scaffold to impart the 
size and shape of intestinal villi. The scaffold was made of collagen and it was seeded with Caco-2 
cells, the system was validated by the testing of Anipyrine [92]. However, one of the main factor 
that is missing in static culture is the shortage of the physiological mechanical microenvironment 
of the normal gut that is subjected to fluid flow and peristaltic motions [94]. To explore these 
physical factors, we developed a microfluidic gut-on-chip device in order to establish an air–
intestinal interface of Caco-2 cells, which is crucial for maturation and terminal differentiation of 
3D human intestinal equivalent (3D-HIE). Bottom-up approach was used to fabricate 3D-ISE 
based on endogenous ECM, obtained by molding of intestinal microtissues (HI-µTP) in a 
maturation chamber for a period of 2 weeks. The combination of such innovative 3D-ISE with 
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microfluidic technology, allowed us to detect the stratification and differentiation of intestinal 
epithelium. Optimized culture conditions were assessed by numerical simulation in order to study 
how the fluid flown conditions guarantee the right oxygen and nutrients supply.  
 
 Materials and Methods 3.2
 Microdevice fabrication 3.2.1
 
The microfluidic gut-on-a-chip device used in this work was fabricated by a rapid prototyping 
procedure. The upper and lower layers of the microfluidic device were prepared by demolding 
polydimethylsiloxane (PDMS) (Sylgard 184, Mascherpa), from a Poly(methyl methacrylate) 
(PMMA, Goodfellow) slab. The PMMA master mold was designed by AutoCAD and carved with 
micromilling machine (Minithech CNC Mini-Mill) making a relief positive geometry to avoid 
silanization process of PDMS. The ratio of PDMS prepolymer and curing agent was 10 : 1 (w/w), 
then the mixture was degassed under vacuum for 20 min to remove air bubbles and then poured on 
PMMA masters. The set-up was incubated at 80 °C for 60 min, then peeled off from master 
molds. Inlet and outlet holes were punched with a 2.5 mm biopsy punch (DifaCooper) while gut 
chamber was punched using a 6.5 mm puncher (Am-Tech). 
The lower layer of PDMS with a central microchannel (1.2 mm wide × 40 mm long ×  0.6 mm 
high) and an intestine chamber (6.5 mm diameter × 0.6 mm high) were bonded, facing upwards, 
to a glass microscope slide  (24 mm wide × 60 mm long) for mechanical support by oxygen 
plasma treatment for 1 min at 50 W in an oxygen plasma oven (Plasma Femto, Diener). 
Polycarbonate porous membrane (0.4 μm diameter of pores, Merck Millipore) was bonded to the 
lower layer using revisited method reported by Chueh et al. [139]. Briefly, pre-cured PDMS was 
spin coated on a glass cover slide for 30s at 750 rpm, PDMS lower layer with recessed 
microchannel was placed in contact onto the glass slide coated with PDMS pre-cured for 30s. 
Then polycarbonate membrane was positioned over the gut chamber using a tweezers and let cure 
at 80 ºC for 30 min. The PDMS upper layer, with a central gut chamber (6.5 mm diameter ×  
5mm high) was bonded to the lower one by oxygen plasma treatment for 1 min at 50 W. The two 
layer were overlapped in order to match the upper and lower gut chambers. Then, the whole setup 
was incubated at 80 ºC overnight to achieve irreversible bonding of the two PDMS layers.  
Before tissue culture, gut-on-chip microdevice, tubes and connectors were sterilized by 
autoclaving. 2-Stop Tygon tubes were inserted into the inlets and outlets of the central channel 
using male luer lock connectors (Harvard Apparatus), then the whole setup was connected to a 
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peristaltic pump (Ismatec) in order to obtain a specific flow rate, 40 μL/min or 1000 μL/min. To 
avoid bacterial contaminations, the intestine chamber was closed laying a 100 μm PDMS 
membrane fabricated by spin coating of PDMS (750 rpm × 30s). 
 Perfusion culture optimization  3.2.2
2% Agarose gel (6.5mm diameter, 1 mm high) was punched with a 6.5 mm puncher. The agarose 
cylinders obtained  were  used to simulate the solidity of the intestinal equivalent. Then the 
agarose disk were accommodated into the intestine chamber of the micro-bioreactor device and 
connected to a peristaltic pump. To simulate medium culture, we used food colouring diluted in 
PBS and then chose different flow rate (0 μL/min; 40 μL/min; 1000 μL/min ) in order to verify at 
which flow rate the agarose disks were completely perfused. We perfused the agarose disk for two 
hours and then the disks were collected to take photographs.  
 Mathematical model CFD simulation 3.2.3
In order to define the experimental setup, the three-dimensional velocity and the oxygen gradients 
in the microbioreactor before in vitro trial, we used the commercial CFD COMSOL Multiphysics 
vers 5. CDF analysis were performed dividing the entire gut-on-chip bioreactor into two different 
domains, a fluid domain indicated with f, which identified the region filled with culture medium, 
and a tissue domain, indicated with t which identified the region filled with the 3D-HIEs and 3D-
ISEs samples. Simulation within the fluid and tissues domain were performed using the steady 
state Navier–Stokes equation, by means of free and porous media flow physic (1). Moreover, the 
simulation for O2 consumption was performed by means of Mass Transport-Convection/Diffusion 
application mode, using transport of diluted species in porous media physic.  Boundary conditions 
were set to reflect flow configuration. Reference pressure was considered at bioreactor outlet (p = 
0 Pa), no slip condition was adopted at the walls, equality for velocity and pressure was imposed 
at the Navier-Stokes (u, v, w, p)/ Brinkman (u2, v2, w2, p2) interfaces. Setting for O2 concentration 
in the culture medium (0.22 mol/m
3
), the diffusion coefficient (D) (10
-9
 m
2
/s), cell density (𝜌) 
calculated in a 1 mm
3
-dermal equivalent (0.2 1014 cell m3 ), maximum velocity of O
2
 diffusion 
(𝑉𝑚𝑎𝑥) (10
-18
 mol/cells/s ) and O2 concentration at 𝑉𝑚𝑎𝑥/2 (𝐾𝑚) (10
3
 mol/m
3
), the convection-
diffusion equation was implemented in the model in order to evaluate the O2 consumption in the 
bio-system. All the setting values were previously evaluated experimentally (data not shown). 
Laminar flow with different flow rates was set at the inlet and zero pressure was set at the outlet.  
𝜇 𝑓∇2𝑣𝑓 = ∇𝑃𝑓           (1)
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Where 𝜇 𝑓 is the dynamic viscosity, 𝑣𝑓 is the fluid velocity, and 𝑃𝑓 is the pressure. Brinkman 
equation (2) was used to describe the flow through the porous medium: 
𝜇𝑡∇2𝑣𝑡 −  
𝐾𝑡
𝜇𝑡
= ∇𝑃𝑡          (2) 
Where 𝐾𝑡 is the hydraulic permeability, 𝜇𝑡is the viscosity of the tissue, and 𝑃𝑡 is the pressure. 
The oxygen concentration within the system was calculated by means of the following mass 
balance equation (3): 
𝐷∇2𝐶 − ∇(𝐶𝑣) = −𝑅          (3) 
Where 𝐶 is the oxygen concentration, 𝑣 is the fluid is the fluid velocity field that was set equal to 
𝑣𝑓 in the domain “f” and 𝑣𝑡in the domain “t” respectively. 𝐷 is the diffusion coefficient of the 
oxygen, set as 𝐷𝑓 in the domain “f” and Dt in the domain “t” respectively. R is the volumetric 
oxygen consumption rate expressed by the Michelis–Menten law and according to the following 
equation (4): 
𝑅 =  𝜌
𝑉𝑚𝑎𝑥𝐶
𝐾𝑚+𝐶
           (4) 
where 𝑉𝑚𝑎𝑥 is the maximum oxygen consumption rate and 𝐾𝑚 is the concentration at which the 
oxygen consumption rate is half of 𝑉𝑚𝑎𝑥, 𝜌 is the cell density in the perfusion chamber obtained 
by taking into account the number of cells present in the 3D-HIE accommodated into the intestine 
chamber of the gut-on-chip device. 𝑅 was set to 0 only in the fluid domain, since cells are present 
only in the tissue domain. The air-liquid interface was mimicked by an open wall at the bottom of 
the intestine chamber.  
 
 Cell type  3.2.4
Caco-2 cells were provided by American Type Culture Collection (ATCC). Cells were sub-
cultured onto 150 mm Petri dishes in Dulbecco Modified E containing 10% fetal bovine serum, 
100 μg mL−1 L-glutamine, 100 U mL−1 penicillin/streptomycin. Cells were maintained at 37 °C in 
a humidified atmosphere containing 5% CO2.  
 Intestinal microtissues precursors: fabrication and 3.2.5
characterization 
Gelatine microbeads having a diameter of 75-150 μm, stabilized by 4% of glyceraldehyde were 
fabricated by means of a modified double emulsion technique (O/W/O) as previously reported 
[85]. Briefly, gelatin (type B Sigma Aldrich Chemical Company, Bloom 225, Mw 176,654 Da) 
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was dissolved into 10 ml of water containing TWEEN 85 (6% w/v) (Sigma Aldrich Chemical 
Company) at 60 °C. Toluene containing SPAN 85 (3% w/v) (Sigma Aldrich Chemical Company) 
was continuously added to the aqueous gelatin solution (8% w/v) to obtain primary oil in water 
emulsion. Microbeads of gelatin containing droplets of toluene were produced through the 
addition of excess toluene (30 ml). After cooling below 5 °C, 20 ml of ethanol were added to 
extract toluene and stabilize gelatin microbeads. The resulting microspheres were filtered and 
washed with acetone and then dried at room temperature. To make the Intestine-
ﬂask bioreactor (250 ml, CELLSPIN, Integra Biosciences) was inoculated with Human 
subepithelial myoﬁbroblasts (ISEMFs) extracted ileal biopsy after informed consent at a cell 
density of 10
5
 cell/ml and a gelatin microbeads density of 2 mg/ml (corresponding to 5x10
3
 
beads/mg), in order to obtain an initial ratio of 10 cells per microbead. The culture suspension was 
stirred intermittently at 10 rpm (5 min stirring and 30 min static incubation) for the ﬁrst 6 h post-
inoculation to allow cell adhesion, and then continuously at 30 rpm up to 10 days [126]. All 
cultures were maintained at 37 °C in a humidified 5% CO2 incubator. Three times per week the 
media was replaced and 2-O-alpha-D-Glucopyranosyl-L-ascorbic Acid 0.5 mM (TCI Europe) was 
added. Human intestine microtissues precursors (HI-μTP) were harvested at different time points 
of spinner cultures to perform the complete characterization.  
 Organotypic intestinal culture development 3.2.6
Three dimensional intestinal stromal equivalents  
3D intestinal stromal equivalents (3D-ISEs) were produced by transferring the HI-µTP into an 
opportunely designed assembling chamber which contains a silicon mold with disk-shaped spaces 
(1 mm in thickness, 5 mm in diameter) where the HI-µTP biological assembling takes place. 
Stainless steel rigid grids are posed directly on the both sides of the system and two 
polytetrafluoroethylene (PTFE) rings are placed on the grids on both sides of the system and are 
fastened to each other by means of stainless steel screws, which close the system and ensure that 
the HI-µTP are retained. The system is autoclavable in each part. Furthermore, the assembling 
chamber was placed on the bottom of a spinner flask and completely bordered by culture medium. 
The spinner was operated at 60 rpm and the medium was exchanged every 3 days. After 2 weeks 
of culture the assembling chamber was opened and the 3D-ISEs were collected. Samples were 
accommodated in transwell insert (diameter, 6.5 mm; Corning) for static culture with basolateral 
chamber filled with 600 μL over a period of 5 to 10 days. At the end of the experiment, 3D-ISEs 
were taken from the insert for further investigation and fixed. 
 
 
61 
 
Three-dimensional human intestine equivalent production  
In order to produce three-dimensional human intestine equivalents (3D-HIEs), organotypic 
epithelial cultures were developed. To this aim, 3D-ISEs (0.5 cm diameter) were rinsed with three 
washes of PBS solution, then the PBS was removed and the 3D-ISEs were accommodate in the 
transwell inserts and allowed to dry for 5 min under laminar flow. Subsequently, 50 μl of the 
Caco-2 suspension was seeded to the centre of each 3D-ISE, corresponding to 2x10
5
 cells/3D-ISE. 
The transwell was incubated for at least 2 hour in incubator at 37°C with 5% CO2 to allow the 
cells to adhere onto the 3D-ISE surface. For static culture, 200 μL of DMEM was added into the 
apical chamber of the transwell insert taking care not to dislodge cells from 3D-ISE and the 
basolateral chamber was filled with 600 µL of DMEM, in order to perform a submerged culture 
that promoted Caco-2 horizontal spreading. Submerged culture lasted approximately 7 days. Then, 
an optimized air-liquid interface culture lasting 2 weeks took place in order to induce the epithelial 
tissues to differentiate and stratify. The culture medium was replenished on the first day and every 
2 days until the end of the experiments. 50 μg/mL of ascorbic acid (l-ascorbic acid, Sigma) were 
added at each medium change. At day 5 and 10, samples were taken from the transwell and fixed 
for further investigation.  
 3D-ISE on a chip and 3D-HIE on a chip 3.2.7
For dynamic culture, 3D-ISE or 3D-HIE (after adhesion of Caco-2) were accommodated into the 
intestine chamber of the gut-on-chip device and connected to a peristatic pump in order to make a 
flow rate of Q= 40 µL/min or Q= 1000 µL/min. For 3D-HIE culture, submerged phase lasted 
approximately 1 day, while air-liquid interface culture lasting from 4 to 9 days for a total culture 
time of 5 or 10 days respectively. At day 5 and day 10, 3D-ISEs were collected form the biochip 
and observed for collagen network imaging. At day 5 and day 10, 3D-HIEs samples were 
collected from the intestine chamber of the biochip and fixed for further analysis.  Multiple chips 
were grown concurrently at 37 ºC in a humidified incubator under 5% CO2 in air over a period of 
5 to 10 days.  
 
 ECM microarchitecture of 3D-ISE 3.2.8
Collagen fraction 
At the end of the experiment tissue samples 3D-ISEs in static and dynamic conditions were 
collected and analysed for collagen network imaging. Two-photon excited fluorescence (Leica 
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TCS SP5 coupled with a Multiphoton Microscope Chamaleon Compact OPO-Vis, Coherent) was 
used to induce Second Harmonic Generation (SHG) and obtain high resolution images of 
unstained collagen structures. SHG images from 3D-ISEs in static and dynamic conditions were 
analysed by using ImageJ software. The collagen fraction in the endogenous ECM space was 
analysed choosing a ROI in order to exclude the signal rising from the microbeads. We define 
collagen fraction (CF) as the ratio between bright pixels to total pixels in the selected ROI, as 
reported in the following the Eq. 1: 
𝐶𝐹 =
𝑁𝐶
𝑁𝐶+𝑁𝐵
                                                 (1) 
where Nc and Nb represent the number of pixel from the collagen and non collagen portion, 
respectively. 
 
Degree of collagen assembly (CA) evaluation 
The degree of collagen assembly (CAD) network was evaluated by analysing the intensity of the 
SHG signal from 3D-ISEs in static and dynamic conditions. The analysis was performed within 
the ECM space where the SHG signal was present. All SHG images were subjected to noise 
subtraction and the average intensity was evaluated as described by Eq. 2:   
CAD ∝ I̅ =
 ∑ Iipi
255
i=1
∑ pi
255
i=1
                                                    (2) 
where I ̅is the average intensity, Ii is the intensity corresponding to the pixel pi, while the index i = 
xi, yi runs in the gray value interval from 1 to 255. The intensity I ̅ of the collagen network is 
known to be proportional to the degree of assembly of the newly synthesized collagen [124]. 
 
Correlation length 
At the end of the experiment tissue samples 3D-ISEs in static and dynamic conditions were 
collected and analysed for collagen network imaging. Two-photon excited fluorescence (Leica 
TCS SP5 coupled with a Multiphoton Microscope Chamaleon Compact OPO-Vis, Coherent) was 
used to induce Second Harmonic Generation (SHG) and obtain high resolution images of 
unstained collagen structures. The samples were observed by using λex = 840 nm (two photons) 
and λem=415-425 nm. The SHG images have a size of 512 × 512 pixels and were acquired with a 
resolution of 8 bit using 40X/1.25 objective. To quantify the stroma related changes, we perform 
Gray-level-Co-occurrence Matrix (GLCM) texture analysis, by using the Image J plug-in 
“Texture” on SHG images [140]. In this work, we calculated the correlation curve (COR) for 
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distances ranging from 1 to 100 pixels in the horizontal (0°) and vertical (90°) direction of each 
optical section that cover a length of interest of 40 μm. In such spatial windows the distance at 
which the correlation function fall off represents the correlation length of the texture. In particular 
correlation curve was calculated versus neighbour index and correlation length was obtained by 
fitting data with an exponential low.  The Eq. 3 of 𝐶𝑜𝑟 is given as below [141]: 
𝐶𝑜𝑟 =  ∑
(𝑖−µ𝑖 )(𝑗−µ𝑗)𝑝(𝑖,𝑗)
𝜎𝑖 𝜎𝑗
𝑖,𝑗                                                                                             
(3) 
where µi, µj, σi and σj  are given by the Eq. (4)-(7):  
μ𝑖 =  ∑ 𝑖 ∗ 𝑝(𝑖, 𝑗)𝑖,𝑗                                                                                                                             
(4) 
μ𝑗 =  ∑ 𝑗 ∗ 𝑝(𝑖, 𝑗)𝑖,𝑗                                                                                                                            
(5) 
𝜎𝑖 =  √∑ (1 − μ𝑖)2𝑝(𝑖, 𝑗)𝑖,𝑗                                                                                                                
(6) 
𝜎𝑗 =  √∑ (1 − μ𝑗)
2
𝑝(𝑖, 𝑗)𝑖,𝑗                                                                                                               
(7) 
In particular p(i,j) is the probability of gray level i occurring next to gray level j, μ𝑖, μ𝑗, 𝜎𝑖 and 𝜎𝑗 
are the means μ and standard deviations 𝜎 of column i and line j of the matrix, respectively [141]. 
All parameters have a maximum value of 1 and a minimum value of 0 or -1 [6]. The Cor curve is 
an index of the architecture of the network, with a fast decay for fine textures and slow decay for 
coarse structure. From the Cor curve it is possible to obtain the correlation length 𝜆, defined as the 
distance at which the Cor decay is equal to 0.5. 
Determination of collagen content 
At day 5 and 10, 3D-ISEs in static and dynamic conditions were collected in a solution of 10% 
neutral buffered formalin for 1 h, rinsed in PBS dehydrated in an incremental series of alcohol 
(75%,85%, 95% and 100% twice, each step 30 min at RT), then treated with xylene (30 min 
twice) and embedded in paraffin. Tissue sections, 5 μm thick, were stained with Picro Sirius Red 
(PSR) (Sigma Aldrich) following standard procedure and analysed by an optical microscope 
(BX53; Olympus). The analysis was performed on Picro Sirius Red stained sections of each type 
of 3D-ISEs at each time points and about 5 region of interests (ROIs) were examined for each 
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section excluding the areas occupied by the microscaffold, since the aim of imaging analysis was 
to investigate the evolution of endogenous ECM composition. Polarized light images of samples 
stained with PSR alone were acquired with an inverted microscope (BX53; Olympus) with a 
digital camera (Olympus DP 21). A linear polarizer was placed between the light source and the 
specimen, while the analyser was installed in the light path between the specimen and the camera. 
The collagen fibre stained with PSR and viewed with polarized light appear green or red 
depending upon fibre thickness, as fibre thickness increases, the colour changes from green to red 
[142]. We used Image J software to quantitatively determine the proportion of different coloured 
collagen fibres. We resolved each image into its hue, saturation and value (HSV) components by 
applying the software’s “colour threshold” function. Only the hue component was retained and a 
histogram of hue frequency was obtained from the resolved 8-bit hue images, which contain 256 
colours. We used the following hue definitions; red 0-51, green 52-120. The number of pixels 
within each hue range was determined and expressed as a percentage of the total number of 
collagen pixels, which in turn was expressed as a percentage of the total number of pixels in the 
image.  
 
 
 Immunofluorescence and histological analysis  3.2.9
At day 5 and 10, 3D-ISE or 3D-HIEs samples in static and dynamic conditions were fixed in a 
solution of 10% neutral buffered formalin for 1 h, rinsed in PBS, dehydrated in an incremental 
series of alcohol (75%,85%, 95% and 100% twice, each step 30 min at RT), then treated with 
xylene (30 min twice) and embedded in paraffin.  
Tissue section, 5 μm thick were stained with haematoxylin and eosin, mounted with Histomount 
mounting solution (Bioptica) on coverslips and the morphological features of 3D-HIEs were 
observed with a light microscope.  
For immunofluorescence staining of 3D-HIEs deparaffinized and reyhdrated 5 μm thick tissue 
sections, were heat-induced epitope retrieval in sodium citrate buffer at pH 6.0 for 5 min at 
97 °C followed by 10 min at 70 °C in uncloaking chamber, washed with PBS containing 0.2% 
Triton X-100, blocked in a standard histoblocking  for 1h at RT, and incubated with rabbit anti-
human Villin (1/250) and ZO-1 (1/50) (Abcam UK) overnight at 4 °C. Then, secondary antibody 
incubation, goat anti rabbit 568 (Alexa Fluor)  (1/500) and goat anti rabbit 488 (Alexa Fluor)  
(1/1000) for villin and ZO-1 respectively was performed, cell nuclei were detected by DAPI 
staining (5 µm/mL, Sigma Aldrich).  
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 Alkaline Phosphatase assay (ALP Activity)  3.2.10
 
In order to evaluate the alkaline phosphatase activity, cell supernatants were collected and were 
processed by using the colorimetric Alkaline Phosphatase Assay Kit (Abcam, Cambridge Science 
Park). The kit uses p-nitrophenyl phosphate as a phosphatase substrate, which turns yellow when 
dephosphorylated by alkaline phosphatase. The absorbance was immediately read at 405 nm using 
a microplate reader (Wallac Victor 3TM; Perkin Elmer), and alkaline phosphatase activity was 
expressed as Unit (U). 
 Statistical analysis 3.2.11
Data are expressed, as mean ± standard deviation and show the results from three independent 
experiments. The differences between two or more groups were evaluated (p value < 0.05) using 
one-way analysis of variance (ANOVA). A Gaussian distribution for each population was 
assumed. For pair-wise comparisons within each experimental group, Tukey’s post-test was used. 
 
 Results 3.3
 Microdevice fabrication 3.3.1
In this work, we designed and fabricated a microfluidic device able to remodel the collagen 
network of the 3D-ISEs samples and to reproduce a dynamic air-liquid interface culture for the 
3D-HIE during culture time. Figure 3.1 shows the microfluidic device configuration composed by 
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a double layer of PDMS with a polycarbonate membrane interposed between the two layers 
 
Figure 3.1: Schematic representation of the gut-on-chip device. (A) Top view of the design of the biochip, (B) Two layer of PDMS 
were bonded on a glass slide, the 3D tissues are accommodated on the polycarbonate membrane between the two layers. (C) 
Frontal view of the microfluidic device. The microchannel is bonded on the glass facing upwards.  
 
(Figure 3.1 B). Firstly, to assess if the biochip could remodel the collagen network and maintain 
an air-liquid interface culture, we placed 3D-ISEs into the intestine chamber for 10 days and 
analysed the ECM remodelling during the culture time. Second, to reproduce ALI culture the 3D-
ISEs were placed into the intestine chamber, seeded with intestinal epithelial cells (Caco-2) and 
cultured for 10 days. The whole setup was connected to a peristaltic pump in order to allow a fluid 
flow condition. The gut-on-chip device was optically accessible for multiphoton microscope in 
order to collect real time evolution of collagen network. To maintain the viability of the  3D-ISEs 
and 3D-HIEs samples the culture conditions were optimized in order to guarantee the correct 
oxygen and nutrients supply and the collagen network assembly.  
 Perfusion culture optimization  3.3.2
In order to choose the better flow rate to guarantee the cell viability, nutrient intake, cell 
differentiation and ECM organization of the both 3D-ISEs and 3D-HIEs, preliminary study were 
performed on the device. Perfusion preliminary test by using agarose disk to simulate the solidity 
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and texture of the samples, were firstly conducted with two different flow rate: 40 μL/min and 
1000 μL/min and 0 μL/min simulate static condition. After two hours of dynamic culture, the 
agarose disks were collected and pictured of the samples were taken, with the purpose to evaluate 
the degree of perfusion of the agarose disk. Figure 3.2-A displayed a gradient of blue starting from 
the bottom of the agarose disk in static condition (Q=0 μL/min) indicating that the apical part of 
the tissues were not nourished. In both Q=40 μL/min and Q=1000 μL/min (Figure 3.2 B-C) the 
agarose disks are completely filled with the blue solution.  
 
Figure 3.2: Agarose cup perfused with PBS and food colouring . (A) Flow rate of 0 μL/min, (B) 40 μL/min and (C) 1000 μL/min.  
In A it is possible to see a more intense colour at the bottom part compared to the top part, in comparison B and C exhibited an 
intense and homogenous colour. 
 
 Mathematical model CFD simulation 3.3.3
With the objective to choose the optimal flow rate to perform the dynamic culture, we carried out 
CFD simulations. We coupled Navier- Stokes equations (1) with Brinkman equation (2), in the 
fluid compartment and in the tissue compartment respectively. Oxygen consumption, by the cells 
contained into the 3D equivalent intestinal tissues, was calculated using a Michelis-Menten 
equation (4), taking into account the diffusive/convective oxygen transport. These numerical 
simulation were performed equation CFD simulations using different flow rate, 0, 40 and 1000 
μL/min. In Figure 3.3 are were reported the colour map of the oxygen profile with black arrows to 
represents  the convective (Figure 3.3 A,D,G) and diffusive transport (Figure 3.3 B,E,H), the light 
blue line represents showed the stream line of velocity field (Figure 3.3 C,F,I). The simulations 
show that at flow rate Q=1000 μL/min, the oxygen concentration was higher in all the part of the 
sample due to the increased contribution of convective transport, since the velocity field was 
higher. Operating in static conditions, flow rate of 0 μL/min, the convective contribution was the 
lowest but the diffusive contribution is not adequate to perfuse and feed all the part of the sample. 
The same situation was presented in the simulation at flow rate of 40 μL/min. A little convective 
contribution was obtained but it is still too low for guarantee the optimal culture conditions. 
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Figure 3.3: CFD simulations using COMSOL Multiphysics. In A-C are reported simulations for convective, diffusive  flux and the 
stream line of the velocity field for the static culture (Q= 0  μL/min), D-F for 40 μL/min and 1000 μL/min 
 Collagen organization 3.3.4
For 3D-ISE on-chip, four samples were cultured in parallel, two in static condition, in a transwell 
insert,  and two in dynamic condition, into the microfluidic device, both for a culture time from 5 
to 10 days. The analysis of the architecture of the ECM was performed at day 5 and 10, for both 
static and dynamic culture, by using MPM that allow to visualize unstained collagen structure. 
Figure 3.4 shows SHG images rising collagen signal of 3D-ISEs in static (Figure 3.4 A-B) and 
dynamic (Figure 3.4 C-D) conditions during all the culture time. The collagen assembly degree 
(CAD) were extrapolated by SHG images (Figure 3.4 E), in particular, according to the above-
mentioned Eq. (2), the measured CAD was higher for 3D-ISEs in dynamic culture where it 
reaches the value of 16,57% ± 4,87% at day 5, and 43.99%  ± 9.84% at day 10. 
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Figure 3.4: SHG signal (gray scale) from fibrillar collagen in (A,C) 3D-ISE in static and dynamic condition at day 5 and in (B,D) 
in 3D-ISE at day 10. Scale bar 100 μm. (E) Collagen assembly degree (CAD) in static and dynamic culture during culture time. (F) 
Collagen fraction (CF) in static and dynamic conditions.  Statistical difference was determined using ANOVA. Asterisks indicate 
statistical difference with p<0.05 
 
In order to quantify the collagen amount SHG image were analysed by image j software. Collagen 
fraction (Figure 3.4 F) graph, showed how the collagen content increase for the samples in 
dynamic conditions with culture time increasing.  
Picro Sirius Red staining allowed monitoring collagen maturation with time. In the Figure 3.5 A-
D representative images of Picro Sirius Red stained 3D-ISE’s section are reported for static and 
dynamic culture at days 5 and 10. Figure 3.5 E-F shows the results from imaging elaboration of 
Picro Sirius Red images indicating that collagen was present at each time point for all the 3D-ISE 
type. The graph showed that the percentage of immature collagen content decrease as culture time 
increase, in particular for the 3D-ISEs in dynamic conditions. On the other hand, percentage of 
mature collagen content increase as culture time increase and for 3D-ISE in dynamic conditions, 
reaching 3.90% ± 1.39% for 3D-ISE at day 10.  
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Figure 3.5: Morphological and compositional features of 3D-ISEs. Picro sirius stained sections (A-D) for 3D-ISE in static and in 
dynamic culture at day 5 and day 10. Quantification of immature and mature collagen fraction (E-F). Asterisks indicate statistical 
difference with p<0.05 
 
To quantitatively assess the collagen-related changes, we applied GLCM texture analysis to the 
SHG images (Figure 3.6 A). The correlation feature extracted from the GLCM provided an 
estimate of collagen fibres organization and structure. By using Gray-Level-co-occurrence-matrix 
(GLCM) we evaluated the correlation (Cor) of the collagen network in order to detect the 
transition of the network from a fine to a wavy architecture (Figure 3.6 B).  
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Figure 3.6: Correlation curve as function of distance in of 3D-ISEs in static and dynamic condition at day 5 and 10 (A). 
Correlation length obtained by fitting parameters from normalized correlation curves (B). Asterisks indicate statistical difference 
with p<0.05. 
 
 
 
 Organotypic intestinal culture development 3.3.5
Intestinal microtissues were transferred in a maturation chamber into a spinner flask in order to 
obtain their moulding in a disk shaped construct (1mm high, 6.4 mm diameter). After two weeks 
the 3D-ISE were collected from the spinner flask and used to perform static and dynamic culture, 
or they were seeded with Caco-2 cells in order to obtain 3D-HIEs samples which are cultured in 
the same static and dynamic conditions. In Figure 3.7 A  is the reported the phase of the μTPs 
loading in the maturation chamber. Figure 3.7-B,C shows how 3D-ISEs looked after two weeks of 
maturation in a spinner flask. The 3D-ISEs removed from the mould disc-shaped, has a 
completely smooth surface, remains intact and shows a certain elasticity and firmness. 
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Figure 3.7: HD-μTPs moulding in the maturation chamber (A); Two pictures(B,C) of the 3D-ISE obtained. The organotypic 
intestinal tissues are smooth and disk shaped after 2 weeks of maturation  
 
 
 Histological analysis 3.3.6
To evaluate the morphological features of the 3D-HIEs, histological analysis were performed. The 
3D-HIEs were stained with Haematoxylin and Eosin at day 5 and 10 in static and dynamic 
conditions, as shown in Figure 3.8. The H&E staining of 3D-HIEs showed the epithelial 
stratification and organization of the samples. For samples in static conditions (Figure 3.8 A,B), 
the epithelial thickness is lower compared to samples in dynamic conditions (Figure 3.8 C,D).  
 
Figure 3.8: Histological images of  Haematoxylin and Eosin  of 3D-HIEs under static (A-B) and dynamic culture (C-D) compared 
at different time point. 3D-HIEs in both static and dynamic condition at day 5 (C) and day 10 (D). Scale bar 50 μm. 
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 Immunofluorescence analysis 3.3.7
In  order to study the epithelial differentiation in static and dynamic air liquid interface conditions, 
we perform immunofluorescence of ZO-1 and villin. In Figure 3.9 and Figure 3.10 are reported 
immunofluorescence images of these markers. As shown in the pictures Figure 3.9, for 3D-HIEs 
in static conditions lower fluorescent of signal is present than samples in dynamic conditions.  
 
Figure 3.9: Immunofluorescence staining of ZO-1  (A-B) and villin (C-D) in static culture conditions. Scale bar 100 μm. 
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Figure 3.10: Immunofluorescence staining of ZO-1  (A-B) and villin (C-D) dynamic culture conditions. Scale bar 50 μm. 
 
As reported in Figure 3.9 and  Figure 3.10, ZO-1 staining is presents for all the samples but at day 
5 the signal its low and not form a grid, instead visible in the 3D-HIEs section at day 10 (Figure 
3.10  B) .  In Figure 3.9 C-D and Figure 3.10 C-D, are represented the immunofluorescence 
images of villin a marker of differentiation expressed in the intestinal micro villi. At day 5 in static 
(Figure 3.9 C) and dynamic conditions (Figure 3.10 C), villin is expressed only in the apical part 
of the epithelium indicating a principle of differentiation, anyway it was not organized as well as 
in the 3D-HIEs at day 10 in dynamic conditions, where it forms a well-oriented epithelium.  
 Alkaline Phosphatase assay (ALP Activity) 3.3.8
With the aim to study the epithelial differentiation, alkaline phosphatase assay was carried out in 
both static and dynamic conditions. In Figure 3.11 the graphs showed the ALP released in the 
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culture media for air liquid interface culture in static and dynamic conditions.  ALP activity is 
higher as time of the culture goes up and in dynamic air liquid interface conditions, indicating 
major cells differentiation. 
 
Figure 3.11: Effect of culture conditions on the epithelial differentiation. Alkaline phosphatase activity in both static and dynamic 
conditions at day 5 and day 10. Asterisks indicate statistical difference with p<0.05. 
 Discussion  3.4
In this work we have designed and fabricated a microfluidic bioreactor able to perform an air-
liquid interface culture of 3D human intestinal equivalent and to maintain viability and cells 
differentiation for the culture time. In the preliminary experiment we tried different flow rate in 
order to choose the better dynamic culture conditions for the 3D-HIEs. In the first part of the study 
we perfused agarose disks to simulate the intestinal tissue equivalent in the gut-on-chip device. 
For the static condition (Q=0 μL/min), there was a non-uniform permeation of the food colouring 
solution, indicating that the apical part of the tissues were not nourished. In both Q=40 μL/min 
and Q=1000 μL/min the agarose disks are completely filled with the blue solution. With the aim to 
assess the optimal dynamic culture conditions, numerical simulation were carried out. The CFD 
simulations showed that at flow rate Q=1000 μL/min, the oxygen concentration was higher in all 
the part of the sample due to the increased contribution of convective transport, since the velocity 
field was higher. Operating in static conditions, the convective contribution was the lowest but the 
diffusive contribution is not adequate to perfuse and feed all the part of the sample. The same 
situation was presented in the simulation at flow rate of 40 μL/min. A little convective 
contribution was obtained but it is still too low to guarantee the optimal culture conditions. 
Taking into account these results, experimental session were carried out for the two culture  
conditions, 0 and 1000 μL/min on 3D-HIE and 3D-ISE. To obtain 3D intestinal stromal 
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equivalent, intestinal μTPs were molded into a maturation chamber in spinner flask, in a tangential 
flow conditions that provide nutrient supply and waste removal during maturation time. 3D human 
intestinal equivalent were obtained by Caco-2 seeding on the 3D-ISE in a transwell insert.  
The maintenance of the 3D-HIEs was assessed by the formation of desired intestinal epithelial 
layers, the integrity of each layer, as well as the differentiation of the epithelium. The H&E 
staining of 3D-HIEs histology sections from day 5 to day 10 demonstrated the integrity of 
intestinal epithelial layers in static and dynamic conditions. Stratification of Caco-2 was observed 
5 days after raising the culture to the air-liquid interface in both static and dynamic culture. 
Maximum stratification was observed at day 10 for samples in dynamic conditions. The 
epithelium appeared well organized and differentiated. For the static culture, the epithelial 
thickness is lower than tissues in dynamic conditions, indicating a lower provision of oxygen and 
nutrients [143]. The dynamic culture into the gut-on-chip device of the 3D-HIEs, mimic the in 
vivo flow of small intestine, leads to an improved gas and nutrients transport. These results are 
confirmed by the numerical CFD simulations. 
To evaluate the formation of a continuous and pluri-stratified cell layer, the tight junctions of the 
Caco-2 cells were stained by immunofluorescence assay of ZO-1. This protein contributes to cell-
cell bonds between cells. A network of ZO-1 was expressed on the tissue section of 3D-HIEs 
samples in both static and dynamic culture conditions. Anyway a more dense grid of this tight 
junction protein is expressed in the 3D-HIEs in dynamic conditions indicating that the fluid flown 
conditions increase the tightness of the intestinal epithelium [144]. Moreover the morphological 
differentiation of Caco-2 cells was investigated by staining villin. Villin is an actin binding protein 
present in the brush border membrane, expressed in particular in villi than in the crypts. This 
differentiation marker was performed on both static and dynamic 3D-HIEs sample. The villin 
signal is higher in the gut-on-chip device indicating that cell differentiation occurs faster in the 
dynamic culture conditions. Higher cells differentiation under dynamic conditions was confirmed 
by ALP assay which shows increased production of this enzyme for 3D-HIEs in gut-on-chip 
device. Our results are in agreement with literature studies, indeed other researchers compared 
dynamic conditions to the static one. Cells cultured on the device exhibited accelerated intestinal 
epithelial cell differentiation, formation of villi-like structures and increased intestinal barrier 
functions [111]. 
In order to estimate the interaction between stroma and epithelium regulate the gut homeostasis 
and disease, we observed ECM organization and remodelling of 3D-ISE in dynamic conditions. 
To achieve that, 3D intestinal stromal equivalents were collected from the spinner flask and 
accommodated into the intestine chamber of the gut-on-chip device.  
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We performed several specific analysis about samples’ ECM remodelling during culture time in 
both static and in microfluidic conditions, using SHG imaging. SHG is becoming an intrinsic 
biomarker to evaluate ECM changes and remodelling, since it leads the visualization and 
quantification of collagen matrix change also in vivo. SHG imaging has been performed on static 
and dynamic 3D-ISEs in order to highlight responsiveness and structural difference in collagen 
organization in fluid flown conditions. In SHG images of 3D-ISEs, in static conditions, the fibres 
appear short, thin, loosely packed. On the contrary in dynamic conditions in the 3D-ISEs image is 
possible to observe an intense SHG signal that displays a denser matrix with collagen bundles 
much tighter more organized. 
Furthermore, we assessed the collagen fibre morphology revealed by SHG in a quantitative 
manner by using texture analysis. One of the most important statistical texture method is the grey 
level co-occurrence matrix (GLCM). In combination with SHG, GLCM is used to quantify the 
collagen fibre size, arrangement and distribution of the collagen fibrillary bundles [145].  
The GLCM characteristic curves calculated, provide information for detailed morphological 
characterization of the collagen fibres, allowing to further sights into various physiological and 
pathological processes, such as the structural modification of the extracellular matrix during the 
migration and invasion of tumour cells. 
We quantified the collagen structure by using GLCM texture analysis and evaluating the 
difference between the more dense fibre then fine fibrils. To achieve this, we performed GLCM 
analysis on 3D-ISEs at day 5 and day 10 in static and dynamic culture condition, the correlation 
curves of all the sample exhibited a decrease of the correlation as pixel distance increase, 
indicating that the collagen matrix is distinct [146]. According to the literature, the correlations 
curves give information about the fibre size of collagen bundles. In particular as reported by Hu et 
al. [147], the collagen fibres size may be estimated by the distance between the y-axis and the first 
valley of the curves. As reported in our correlations curve the 3D-ISEs in dynamic conditions at 
day 10 exhibited the higher correlation curves, followed by the sample at day 5. The lowest 
correlation curves was obtained for the 3D-ISEs at day 5 in static conditions, indicating smaller 
and thin collagen fibre. These results indicates that the endogenous ECM of the 3D-ISE is 
subjected to a faster remodelling in dynamic conditions. This data is also confirmed by the CAD 
analysis which shows higher assembly degree of collagen in dynamic conditions.  
About the quality of the collagen fibre, we performed Picro Sirius Red staining, leading us to 
evaluate the level of maturation of collagen fibre. The colour of collagen fibres stained with Picro 
Sirius Red and viewed with polarized light depends upon fibre thickness; as fibre thickness 
increases, the colour changes from green to red [140]. In our experiments, mature collagen content 
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increased in dynamic conditions and as culture time rose. On the contrary, immature fibre content 
goes down for sample in microfluidic flown conditions. This results are in agreement with 
previous studies in which it was assessed that Caco-2 cells exhibit higher proliferation, increased 
production of phosphatase alkaline when cultured in presence of ECM protein like collagen and 
laminin, despite of plastic surfaces [148]. 
 Conclusion  3.5
In this study, we demonstrated a microfluidic platform that allows long term maintenance of 3D-
HIEs and 3D-ISE in an air-liquid interface culture in micro-scale setting, for the purpose of drug 
testing and intestinal absorption evaluation. The dynamic fluid flown conditions allows more 
stratified and differentiated epithelium in less time compared to the conventional transwell culture. 
Since the interaction between cells and ECM are fundamental to maintain the homeostasis of the 
tissues, we assessed ECM organization in our gut-on-chip device concluding that the gut-on-chip 
is valid to speed up the remodelling processes. 
The gut-on-a-chip, along with the mathematical model described here, can be used to estimate 
intrinsic intestinal transport properties and the effects of ingested nanoparticles. Overall, the gut-
on-a-chip is a user-friendly and cost-effective in vitro platform for drug testing of candidate 
molecules for intestinal first-pass evaluation.  
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Chapter 4  
4 Human first-pass metabolism on a chip  
 Introduction 4.1
The two organ that play a major role in the process of absorption, distribution, metabolism and 
excretion of xenobiotics (ADME) are the liver and the intestine. Oral administration of drugs is 
the most preferred route of administration because it is easy and comfortable for the patients.  
After oral absorption, xenobiotics are eventually absorbed from the small intestine, thanks to its 
particular physiological properties with folds, villi and micro villi. Xenobiotics may further be 
metabolized by intestine, through an intestinal first-pass effect. Then and other metabolites are 
directed to the liver where they are further metabolized, excreted and more generally detoxified.  
The intestinal and the hepatic first-pass effects is involved mainly in the reduction of 
bioavailability of drugs and xenobiotics, which is important for the study of this two organs, both 
in terms of the development of new therapeutic substances, but also for toxicity testing [149]. For 
this reason, it is fundamental to study their functionalities with experiment  performed in vivo and 
in vitro. However, conventional in vitro and in vivo testing are really expensive, rise ethical 
problems and are unable to reproduce accurately the cellular response of the intestine and liver 
[150]. Typical methods consist in static cell culture of human cell line in Petri dish or in transwell 
insert. 2D cultures are really easy to handle and are commonly used to monitor the metabolism 
and toxicity of xenobiotics on a short term, but they have the disadvantages of not recapitulating 
the in vivo cellular microenvironment. In this culture conditions, primary cells dedifferentiate 
quickly and exhibit low metabolic activity, implying low predictability of those models [151]. 
New in vitro platform have been established in recent years to overcome these problems. One of 
these models consists of using microfluidic devices, which exhibit many advantages like the better 
control of the microenvironment, the state of differentiation of the cells and the perfusion new 
medium continuously [152]. Using microfluidic device it is possible to recreate organ to organ 
interaction in order to mimic first-pass metabolism between intestine and liver. Several model 
have been proposed in the last years.  For example, Prot et al. developed polycarbonate bioreactor 
where the Caco-2 cells were cultivated on a conventional cell culture insert. The insert was then 
incorporated into a dedicated fluidic platform that could be coupled with a microfluidic biochip 
which is cultivated with HepG2/C3a, freshly isolated rat primary hepatocytes and human 
cryopreserved hepatocytes, for comparative purposes. First-pass intestinal absorption and liver 
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metabolism were studied using phenacetin. In addition, a mathematical model was built based on 
the experimental data. The corresponding PK model was used to estimate the kinetic parameters 
describing the transfer of the molecule across the intestinal barrier, as well as intestinal and 
hepatic clearances. Finally organ mathematical models were used to predict situations in humans 
[116]. However, this kind of model lack of the three dimensional architecture and also the 
experimental set-up is quite bulky. Since 3D culture replicate better the hepatic and intestinal in 
vivo physiologic environment,  Midwoud et al. designed a microfluidic system for the purpose of 
investigating inter-organ effects, made by coupling two micro-chambers, one containing an 
intestinal tissue slice, the other a liver slice, which can be sequentially perfused. In this way, 
metabolites formed by the intestine in the first chamber can be directed to the liver in the second 
chamber for further metabolism, thereby mimicking in vivo, first-pass metabolism [117]. 
Nevertheless, tissues slices have poor availability, especially for human tissues, lose viability in 
few days of culture, and are difficult to use in high-throughput studies, making this model not so 
convenient. In perspective, in order to combine 3D tissues and microfluidic devices, we design 
and developed a microfluidic device which interconnect 3D human intestinal equivalent (3D-HIE) 
and HepG2-microtissues in a perfusion microdevice. 3D-HIE were obtained by bottom up 
approach, using intestinal microtissues moulded into a maturation chamber. The biochip 
recapitulate the intestinal and hepatic first-pass mechanism of ethanol using a selective transport 
from the upper to the lower part of the device.  
 
 Materials and Methods  4.2
 Cell type 4.2.1
HepG2 were provided by American Type Culture Collection (ATCC). Cells were sub-cultured 
onto 150 mm Petri dishes in Minimum Essential Medium Earle’s Salt (Microtech) containing 10% 
fetal bovine serum, 100 μg mL−1 L-glutamine, 100 U mL−1 penicillin/streptomycin,  0.1 mM Non 
Essential Amino Acid and 0.1 mM Sodium pyruvate. Caco-2 cells were provided by American 
Type Culture Collection (ATCC). Cells were subcultured onto T-flask in Dulbecco Modified 
Eagle Medium with 10% of fetal bovine serum, 100 μg mL−1 L-glutamine, 100 U mL−1 
penicillin/streptomycin. Cells were maintained at 37 °C in a humidified atmosphere containing 5% 
CO2. Culture medium for fist-pass metabolism on chip was obtained using HepG2 and Caco-2 
medium in 1:1 ratio.  
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 Intestinal microtissue precursors: fabrication and 4.2.2
characterization 
Gelatine microbeads having a diameter of 75-150 m, stabilized by 4% of glyceraldehyde were 
fabricated by means of a modified double emulsion technique (O/W/O) as previously reported 
[85], [126]. Briefly, gelatine (type B Sigma Aldrich Chemical Company, Bloom 225, Mw 176,654 
Da) was dissolved into 10 ml of water containing TWEEN 85 (6% w/v) (Sigma Aldrich Chemical 
Company) at 60 °C. Toluene containing SPAN 85 (3% w/v) (Sigma Aldrich Chemical Company) 
was continuously added to the aqueous gelatine solution (8% w/v) to obtain primary oil in water 
emulsion. Microbeads of gelatine containing droplets of toluene were produced through the 
addition of excess toluene (30 ml). After cooling below 5 °C, 20 ml of ethanol were added to 
extract toluene and stabilize gelatine microbeads. The resulting microspheres were filtered and 
washed with acetone and then dried at room temperature. To make the intestine-TP, spinner ﬂask 
bioreactor (250 ml, CELLSPIN, Integra Biosciences) was inoculated with Human sub-epithelial 
myoﬁbroblasts (ISEMFs) extracted ileal biopsy after informed consent at a cell density of 105 
cell/ml and a gelatin microbeads density of 2 mg/ml (corresponding to 5*10
3
 beads/mg), in order 
to obtain an initial ratio of 10 cells per microbeads. The culture suspension was stirred 
intermittently at 10 rpm (5 min stirring and 30 min static incubation) for the ﬁrst 6 h post-
inoculation to allow cell adhesion, and then continuously at 30 rpm up to 10 days [126]. All 
cultures were maintained at 37 °C in a humidified 5% CO2 incubator. Three times per week the 
media was replaced and 2-O-alpha-D-Glucopyranosyl-L-ascorbic Acid 0.5 mM (TCI Europe) was 
added. Human intestine microtissue precursors (HI-TP) were harvested at different time points of 
spinner cultures to perform the complete characterization.  
 
 Three-dimensional human intestine equivalent production  4.2.3
3D intestinal stromal equivalents (3D-ISEs) were produced by transferring the HI-TP into an 
opportunely designed assembling chamber which contains a silicon mold with disc-shaped spaces 
(1 mm in thickness, 5 mm in diameter) where the HI-TP biological assembling takes place. 
Stainless steel rigid grids are posed directly on the both sides of the system and two 
polytetrafluoroethylene (PTFE) rings are placed on the grids on both sides of the system and are 
fastened to each other by means of stainless steel screws, which close the system and ensure that 
the HI-TP are retained. The system is autoclavable in each part. Furthermore, the assembling 
chamber was placed on the bottom of a spinner flask and completely bordered by culture medium. 
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The spinner was operated at 60 rpm and the medium was exchanged every 3 days. After 2 weeks 
of culture the assembling chamber was opened and the 3D-ISEs were collected. Samples were 
accommodated in transwell insert (diameter, 6.5 mm; Corning) for static culture with basolateral 
chamber filled with 600 μL over a period of 5 to 10 days. At the end of the experiment, 3D-ISEs 
were taken from the insert for further investigation and fixed. 
In order to produce three-dimensional human intestine equivalents (3D-HIEs), organotypic 
epithelial cultures were developed. To this aim, 3D-ISEs we obtained as reported in Par. 3.2.5(0.5 
cm diameter) were rinsed with three washes of PBS solution, then the PBS was removed and the 
3D-ISEs were accommodate in the transwell inserts and allowed to dry for 5 min under laminar 
flow. Subsequently, 50 μL of the Caco-2 suspension was seeded to the center of each 3D-ISE, 
corresponding to 2x10
5
 cells/3D-ISE. The transwell insert was incubated for at least 2 hours in 
incubator at 37°C with 5% CO2 to allow the cells to adhere onto the 3D-ISE surface. Then 200 L 
of DMEM was added into the apical chamber of the transwell insert taking care not to dislodge 
cells from 3D-ISEs and the basolateral chamber was filled with 600 L of DMEM, in order to 
perform a submerged culture that promoted Caco-2 horizontal spreading. Submerged culture 
lasted approximately 7 days. Then, an optimized air-liquid interface culture lasting 2 weeks took 
place in order to induce the epithelial tissues to differentiate and stratify. The culture medium was 
replenished on the first day and every 2 days until the end of the experiments.  
 HepG2-Microtissues production  4.2.4
All cell cultures on microscaffolds were performed in spinner flask (Integra). Briefly, 35 mg of 
GPMs were loaded with 5,25 × 106cells (30 cell/GMP ratio). To promote cell seeding on GMPs 
an intermittent stirring regime (30 min at 0 rpm, 5 min at 30 rpm) for 24 h. After seeding, the 
stirring speed was kept at a continuous 30 rpm for up to 14 days. Culture medium were changed 
every two days. All cultures were maintained at 37 °C in a humidified 5% CO2 incubator. The 
HepG2 microtissues precursors obtained (HepG2-µTPs) samples were taken for further 
investigations at days 3, 5, 7, 10 and 14 and fixed for further investigations. 
 Microfluidic device fabrication 4.2.5
The microfluidic first pass-on-a-chip device used in this work was fabricated by a rapid 
prototyping procedure. The PMMA master mold was designed by AutoCAD and carved with 
micromilling machine (Minithech CNC Mini-Mill) making a relief positive geometry to avoid 
silanization process of PDMS. The ratio of PDMS pre-polymer and curing agent was 10 : 1 (w/w), 
then the mixture was degassed under vacuum for 20 min to remove air bubbles and then poured on 
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PMMA masters. The set-up was incubated at 80 °C for 60 min, then peeled off from master 
molds. Inlet, outlet and µTPs holes were punched with a 2.5 mm biopsy punch (DifaCooper) 
while gut chamber was punched using a 9.5 mm puncher (Am-Tech). Then the PDMS device was 
bonded to a glass microscope slide  (24 mm wide × 60 mm long) by oxygen plasma treatment for 
1 min at 50 W in an oxygen plasma oven (Plasma Femto, Diener). 
The devices is divided into two parts, the gut and the liver part which are connected by a central 
channel. The gut part was designed with a central microchannel (1.2 mm wide × 40 mm long ×  
0.6 mm high) which transported the medium into a gut chamber (9.5 mm diameter × 5mm high). 
The liver part, communicate with the central gut microchannel which was separated from three 
parallels tissue chamber (0.5 mm wide ×0.3 mm high × 1 mm long) by small pillars (0.100 mm 
diameter × 0.09 mm pillar interspace). A middle collection channel (0.5mm wide × 0.3 high) was 
used to collect tissue supernatants. 
Finally the PDMS layer was bonded to glass coverslip by oxygen plasma treatment for 1 min at 50 
W. Then, the whole setup was incubated at 80 ºC overnight to achieve irreversible bonding of the 
two PDMS layers. Then a transwell insert was placed into the 9.5 mm holes of the biochip. To 
obtain the selective transport of fluid from the apical part of the epithelium to the basal part, then 
to the liver compartment, sealing gasket were fabricated. In particular, PDMS gasket was 
fabricated by punching of 1 mm thick PDMS layer, first with a 4 mm puncher (for the inner hole) 
and then with a 6.5 mm puncher (for the outer hole). PMMA hollow cylinder (5 mm high, 1 mm 
thick) was fabricated with Micromilling machine. Once transwell insert with 3D-HIE was inserted 
into the biochip, PDMS gasket was placed over the surface of the 3D-HIE. Then PMMA cylinder 
was put in the transwell insert. To avoid bacterial contaminations, the intestine chamber was 
closed laying a 100 μm PDMS membrane fabricated by spin coating of PDMS (750 rpm × 30s). 
The PDMS biochip was sterilized by autoclave, while PDMS gasket and PMMA cylinder were 
sterilized by UV light.  
 First-pass on a chip culture conditions 4.2.6
The perfusion culture of first-pass device was structured into different phases. The first phase was 
devoted to the Caco-2 differentiation over 3D-HIEs surface for a period of 21 days. The second 
phase was focused on the fabrication of the HepG2-μTP in a spinner flask bioreactor 4.2.4, then 
the third phase consists in the accommodation of transwell insert, gasket and PMMA cylinder into 
the first pass device, at the same time HepG2-μTPs from day 5 to 7 were collected from the 
spinner flask and loaded into the first-pass device. The final phase consists into the connection of 
all the experimental set-up to a syringe pump. Since the gut epithelium was already stratified we 
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didn’t have to use the flow rate used for gut-on-chip device (Q= 1000 µL/min) (as reported in 
3.2.7), moreover this flow rate could carry away the HepG2-µTPs loaded into the biochip. 
Whereby, the final flow rate of the first-pass-on-chip device was set to 5 μL/min. Culture medium 
was a combination of half HepG2 medium and half Caco-2 medium. To simulate oral ingestion of 
compounds, 300 μL of culture media diluted with 400 mM of 100% ethanol were diluted in 
culture medium and added in the PMMA cylinder over the 3D-HIE. In each experiment three 
parallel device were carried out, one without ethanol treatment, two treated with ethanol 400 mM, 
one stopped after 24h and the second after 48h of culture.  
 Measurement of selective permeation properties 4.2.7
To simulate oral drug ingestion and selective permeation of compounds, 5 µg/ml of  3KDa FITC-
Dextran solution were dissolved in HepG2-Caco-2 medium and flew in the first pass device for 
24h and 48h.  At each time point Dextran permeation measurements were conducted with a laser 
scanning microscope (TCS SP5, Leica). Samples were illuminated with a 25X (NA 0.95) 
objective and 488 nm excitation line from Argon laser operating with 5% output power. 
 Immunofluorescence assay  4.2.8
At 24h and 48 h, 3D-HIEs samples were withdrawn from the first-pass device and fixed with 4% 
paraformaldehyde for 20 min and then rinsed in PBS. For immunofluorescence staining of 3D-
HIEs, samples were incubated inti permeabilizing solution (0.2% Triton X-100 + 3%BSA + PBS) 
for 10 min. After blocked for 1h at RT, primary antibody (anti-human Claudin-1, 1/40, Abcam) 
was incubated for 1h at RT. Then, secondary antibody incubation, goat AlexaFluor 546-
conjugated anti-rabbit IgG antibodies was incubated for 1h. Cells nuclei were detected by DAPI 
staining (5 µm/mL, Sigma Aldrich).  
 
 Alcohol dehydrogenase release assay 4.2.9
The culture media supernatant from first-pass on chip device each devices was collected for the 
evaluation of alcohol dehydrogenase (ADH) release. Culture media supernatants accumulated in 
the reservoir and in the PMMA well, were collected and stored at -20 °C before being analysed. 
ADH activity was performed, using Alcohol Dehydrogenase Activity Detection Kit (Abcam) 
according to the  manufacturer's protocol. Briefly, 50 μL of sample or NADH standard were added 
to a well of a 96-well microtiter. Then reaction mix was added to each well and after 2-5 min the 
absorbance at 450 nm was measured using a microplate reader, in this way a 𝑇𝑖𝑛𝑖𝑡𝑖𝑎𝑙 was fixed. 
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Subsequent measurement were lead every 5 min until the value of the most active sample is 
greater than the value of the highest standard, the time of the penultimate reading is 𝑇𝑓𝑖𝑛𝑎𝑙 . The 
ADH activity was evaluated by the following equation: 
𝐴𝐷𝐻 =
𝐵 × 𝑆𝑎𝑚𝑝𝑙𝑒 𝑑𝑖𝑙𝑢𝑖𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟
𝑅𝑒𝑎𝑐𝑡𝑖𝑜𝑛 𝑡𝑖𝑚𝑒 × 𝑉
 
Where B is the amount (nmole) of NADH generated between 𝑇𝑖𝑛𝑖𝑡𝑖𝑎𝑙  and 𝑇𝑓𝑖𝑛𝑎𝑙 , reaction time is 
the difference between 𝑇𝑓𝑖𝑛𝑎𝑙 and 𝑇𝑖𝑛𝑖𝑡𝑖𝑎𝑙  , and V is the sample volume. ADH was expressed as 
mUnit/mL.  
 
 
 Statistical analysis  4.2.10
The differences between two or more groups were evaluated (p value < 0.05) using one-way 
analysis of variance (ANOVA). A Gaussian distribution for each population was assumed. For 
pair-wise comparisons within each experimental group, Tukey’s post-test was used. 
 Results 4.3
 Microfluidic device fabrication 4.3.1
We developed a microfluidic device to replicate first pass metabolism mechanism. The Figure 4.1 
A shows the geometrical configuration of the biochip, composed by an intestine compartments 
filled where a transwell insert accommodated inside filled with the 3D-HIE, after 21 days of air-
liquid culture. PDMS gasket and PMMA cylinder were used to avoid that non selective passage of 
the compound, form the apical side to the basolateral part. The liver’s part is designed as 
previously described in par. 2.10. The HepG2-µTPs were collected from the spinner flask form 
day 5 to 7 because the exhibit the best performance in terms of viability and hepatic functionality, 
as reported in Chapter 2. They loaded into the liver compartment by pipetting via the three 
appropriate inlet. The entire set-up was connected to a syringe pump (flow rate 5 µL/min) and a 
reservoir in order to have a dynamic fluid flow condition and to collect the tissues supernatants 
respectively. Figure 4.1 B shows the top view of the first pass bioreactor.  
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Figure 4.1: (A) Lateral view of the first pass bioreactor with details of each sealing part in order to have selective permeation of 
the drug. (B) Top view of the first pass device  that shows inlet, outlet and HepG2-µTPs port. Whole set-up was connected to a 
syringe pump. 
 
 
 Measurement of selective permeation properties 4.3.2
In order to study the selective transport of drugs from the bottom part of the device, we simulate it 
by using 3kDa FITC-Dextran. Dextran was diluted in the perfusion culture media and added to the 
apical part of the gut compartment, using PMMA cylinder as a well. After 24h, confocal images of 
the 3D-HIE and HepG2-µTPs were taken in order to evaluate if dextran solution crossed and 
permeated 3D-HIE (Figure 4.2) .  
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Figure 4.2: FITC Dextran 3kDa and DAPI cells staining images of 3D-HIE(A,B) and HepG2-μTPs (C,D) after 24h of perfusion 
culture into the microfluidic first-pass device. Scale bar 75 μm. 
 
 Immunofluorescence assay 4.3.3
To determine the effect of ethanol on the integrity of the tight junctions, 3D samples were stained 
for claudin-1. In Figure 4.3 were reported the images of this tight junction marker. Higher 
expression intensity of claudin-1 was observed for control group 3D-HIE compared to the ethanol 
treated group at 24h (Figure 4.3 B) and 48h (Figure 4.3 C). 
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Figure 4.3: Imunofluorescence of 3D-HIE for claudin-1 for control  (A) at 24h and ethanol treated group at 24h (B) and 48h (C).  
Scale bar 100 μm.  
 Alcohol dehydrogenase release assay 4.3.4
In order to evaluate the metabolic activity of the gut and liver tissues equivalent we measured the 
release of alcohol dehydrogenase, an enzyme which plays a crucial role in ethanol metabolism. 
Measurement of ADH activity in the eluent showed that both hepatic and intestinal cells produced 
this enzyme during culture time, in response to ethanol treatment. Exposure to ethanol levels at 
400 mM resulted in an higher ADH released in tissues supernatant of both gut and liver tissues 
equivalent, compared to the only gut contribution (Figure 4.4).  
 
 
89 
 
 
Figure 4.4: Alcohol dehydrogenase release assay after 24h and 48h  of 400 mM ethanol treatment. Tissues supernatants were 
collected from the PMMA cylinder, for the contribution only of 3D-HIE, and from the reservoir for the contribution of both 
HepG2-μTP  and 3D-HIE.  
 Discussion 4.4
Intestinal and hepatic first-pass metabolism may depress extensively the bioavailability of drugs 
and xenobiotics compounds. Routinely classical in vitro studies consist of drug exposure of 
hepatocytes cultivated in suspension or in monolayer and in a monolayer in Petri dishes. 
Moreover, in vitro and in vivo oral bioavailability extrapolations are calculated using separate in 
vitro data obtained from cultures of Caco-2 (mainly permeability data) and of hepatocytes [153].  
In this chapter we want to recreate and study the first-pass metabolism mechanism into a 
microfluidic device. Through the microfluidic device it was possible to simulate the in vivo route 
of orally ingested compound. To mimic such complex mechanism, we integrated on a chip the two 
mainly involved organs: gut and liver. For both gut and liver model we used 3D tissues engineered 
in vitro. In particular we recreate human intestinal equivalent by bottom up approach using 
fibroblast intestinal microtissues molded into a maturation chamber. We also developed HepG2-
μTP obtained by dynamic cells seeding in a spinner flask bioreactor. In the chapter 2 and 3 we 
showed the dynamic culture in a microfluidic device for liver and gut model respectively. The 
connection between this two organ allows us to mimic the intestinal and hepatic first-pass 
metabolism on a chip. In the first part of the work we designed a microfluidic device, which it was 
constituted of the combination of the liver and gut on chip device. The main problem of the 
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recreation of first-pass metabolism is the maintenance of a selective transport route from gut to the 
liver part. To achieve this, we fabricated a kind of sealing chamber using a PDMS gasket 
accommodated over the 3D-HIE and a PMMA cylinder, acting as a well. To assess the permeation 
properties of the entire set up, we used FITC dextran. Dextran was diluted into the culture medium 
and added to PMMA cylinder, on the apical part of the 3D-HIE. Dextran solution perfuse the 3D-
HIE space and reach the liver compartment, as demonstrated by confocal images after 24h of 
culture. Ethanol was selected as a model molecule to test if the gut-liver chip can reproduce first-
pass metabolism of orally taken drugs. The staining of the nucleus and the claudin-1 of Caco-2 
was performed to characterize the cell layer on the 3D-ISE after 24h of integration in the first-pass 
on chip device. Claudin is a transmembrane protein of tight junction. Tight junctions are 
fundamental in the studies of absorption and permeation of compounds, because they form a 
physical barrier to the diffusion of macromolecules. Loss of the tight junctions barrier leads to an 
higher absorption of toxin and xenobiotic compounds. Previous studies demonstrated that 
acetaldehyde rather than ethanol can cause the disruption of tight junctions in Caco-2 monolayer 
[154]. About this, the major pathway of oxidative metabolism of ethanol in the liver, involves 
alcohol dehydrogenase (ADH). Acetaldehyde is the metabolism product of the ADH. This  
compound is highly reactive and toxic so its accumulation cause the destabilization of the tight 
junctions and incremented permeation of endotoxin which play a crucial role in alcoholic liver 
disease[155],[156]. With the aim to assess the metabolic activity of ADH in our model we 
performed ADH release assay, collecting tissues supernatants. ADH measurement assessed that 
the contribution of 3D-HIE only leads to a lower contribution of the release of this enzyme.  
 
 Conclusion 4.5
 
In this study, we developed a microfluidic gut-liver with an aim of reproducing the first pass 
metabolism. 3D hepatic and intestinal equivalent were accommodated inside the chip and co-
cultured in successful way verified by the dextran permeation assay. Changes in the metabolic and 
absorptive properties of both gut and liver cells were observed. Using ethanol as a model 
xenobiotics, we have shown that this device can be used as a tool to reproduce the first pass 
metabolism of drugs and xenobiotics. Although several improvements are still needed for more 
accurate reproduction of a PK profile, we think that our proposed model is a more predictive 
platform than cell culture in monolayer and resembles the physiological way route of the in vivo 
first-pass metabolism.  
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Chapter 5  
5 Future perspectives 
In this thesis we want to propose a platform to reproduce in vitro the first-pass metabolism’s 
mechanisms. We focused on the two mainly involved organs in this mechanism , the liver and the 
gut. About liver, we firstly started to identify the 3D tissues that better reproduce the liver 
microarchitecture and functionality. We carried out a detailed comparison between two 3D model, 
spheroids, the most used three dimensional in vitro model, and the microtissues, our proposed 3D 
model. We demonstrated that the microtissues were more viable and functional during all the time 
of the culture then the spheroids, moreover the microtissues shows higher yield, are more easy to 
handle and are more suitable for long term culture. Since microtissues are a more predictive model 
of the liver physiology, we loaded them into a microfluidic device, which mimic the functional 
unit of the liver, the hepatic lobule. This biochip allowed the dynamic culture of the HepG2-µTPs, 
ensuring the maintenance of viability and it has been validated using ethanol, one of the major 
hepatotoxic compounds. However, this proposed model need to be optimized for several reasons. 
First of all, we used HepG2 cells that is an immortalized cell line, really easy to handle but with 
low expression of the specific hepatic markers. For this reason, the next step is to consider the 
possibility to use primary hepatocytes, in order to make this novel platform more similar to the 
human hepatic in vivo microenvironment. One other possibility to address is to consider the use of 
iPSC-derived human liver cells. Ultimately, personalized drug screening on mature iPSC-derived 
human liver cells could potentially allow custom drug therapies for different patients. Our liver-
on-chip device allows the possible co-culture with non-parenchymal cells serving as  a functional 
platform for understanding functional maintenance, cell–cell communication, cytotoxic 
metabolism, and inflammatory cascade in a liver sinusoid.  
About gut-on-chip device, presented in the third chapter, we developed first a three dimensional 
intestinal tissue equivalent, obtained by bottom-up approach. The biohybrid is obtained by 
molding of intestinal fibroblasts microtissues into a maturation chamber. Once a 3D disk-shaped 
tissue was obtained, it was seeded with an intestinal epithelium using Caco-2 cell line. In this 
study, our aim was to compare the conventional static air-liquid culture, obtained in transwell 
insert, with a dynamic one using a microfluidic device. We proved that the shear stress imposed 
by the perfusion culture, allows the faster organization of the extracellular matrix secreted by the 
intestinal fibroblasts and assembled during the maturation step, compared to the static culture. 
Other important advantage of the dynamic culture, was expressed by the faster stratification and 
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differentiation of the gut epithelium, already after 5 days. The over mentioned model paves the 
way to new developed platform to assess the intestinal absorption of drugs, nutraceuticals and 
nanoparticles. The device can be adapted to reproduce human gut microbiome to provide a 
versatile platform for other host-microbiome ecosystems that can be found in various human 
organs, which may facilitate in vitro study of the role of human microbiome in orchestrating 
health and disease. About the biochip itself, it can be useable for the air-liquid culture of other 
epithelium like dermal or pulmonary ones.   
In last part of the thesis we conclude the study of first-pass metabolism by introducing a simple 
microfluidic device which interconnect gut and liver, with the aim to simulate the anatomic and 
physiological connection. The proposed biochip, allowed the selective communication and 
passage of compound from the intestinal lumen to the liver tissues. Although other experiments 
needs to be performed,  the biochip open the way to reproduce the first-pass metabolism of drugs 
and to resemble the in vivo condition in a more predictive way compared to conventional gut/ liver 
monoculture. With this new tool, it should be possible to gain a better insight into inter-organ 
interactions and elucidate unknown mechanisms involved in toxicity, gene regulation and drug–
drug interactions. Accordingly, this microflow system will help minimize the gap between the in 
vitro and in vivo situation, and will moreover contribute to the reduction of the use of 
experimental animals. 
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